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CHAPTER 1: INTRODUCTION
1.1 Protein quality control in the endoplasmic reticulum
 At its most basic level, cellular life is dependent on the progression of genetic 
information being converted from DNA into RNA and culminating into proteins. Due to 
intrinsic mechanisms dedicated to ensuring the accuracy of genomic replication, 
prokaryotic and eukaryotic error rates  are lower than 1x10-8 and 1x10-10 respectively [1]. 
The chance of error increases significantly during transcription (1x10-4 per codon in 
prokaryotes [2]) and translation (1x10-3-4 in prokaryotes  [1, 3]). Additionally, the fidelity of 
protein folding in the endoplasmic reticulum (ER) can be low due to the crowded nature 
of molecular activity where the protein concentration can reach as high as  300 mg/mL 
[4]. Simple proteins can fold quickly with relative ease (estimated around 50 ms [4]), 
whereas other, more complex protein complexes can take hours to reach their native 
conformation [4]. Evolutionary advancements in cellular machinery have allowed cells  to 
complete their tasks, such as protein synthesis, with greater efficiency; however, this 
may involve sacrificing the proper maturation of proteins for a faster overall mechanism, 
yielding more product. To combat this, the cell has developed quality control systems to 
help remove proteins  that are not properly folded, and in the ER specifically, ER-
associated degradation (ERAD) is devoted to safeguarding the maturation of secretory 
and endocytic proteins.
1.1.1 The degradation of ER proteins - a history
 For many years, the lysosomal pathway, through a process known as autophagy, 
was thought to handle the removal of anomalous or unused secretory and endocytic 
proteins [5]. This  was the assumption due to formation of lysosomes from vesicles in the 
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Golgi apparatus and their trafficking through the secretory pathway, and the similar 
route travelled by proteins that failed quality control tests [6-8]. 
 The dogma of how secretory proteins were degraded began to change after 
experiments were performed examining the question if proteins are degraded prior to 
reaching the lysosome and if the ER played a role in the quality check of secreted 
proteins. Using T-cell receptor subunit α (TCRα), it was demonstrated that this protein 
was indeed degraded prior to reaching the Golgi and was independent of the lysosome 
[9, 10]. A few years after these initial reports, it was discovered in yeast that the E2 
ubiquitin-conjugating enzyme UBC6 mediated the degradation of some proteins in the 
ER. In this case, the presence of UBC6 null mutants prevented the removal of mutant 
Sec61 (a component of the ER translocon) from the ER [11]. Further evidence showed 
the stabilization of ER protein substrates via proteasome inhibition in human cells and in 
yeast [12]. Together, these data helped change the lysosomal-dependent theory  of 
secretory protein degradation to the idea that misfolded proteins are removed from the 
ER, transported into the cytosol, and degraded by the proteasome.
1.1.2 Substrate misfolding 
! Despite complex molecular machinery in place to ensure the proper maturation of 
polypeptides that enter the ER, protein misfolding is inevitable. To ensure that misfolded 
proteins do not accumulate, anomalous proteins are degraded as they are recognized. 
In ERAD, misfolded proteins are recognized, ubiquitinated and extracted into the cytosol 
to be degraded by the proteasome [13]. 
" Cells are under constant stress associated with the accumulation of misfolded 
proteins. It is estimated that around one-third of the polypeptides that enter the ER are 
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degraded [14]. Misfolding can occur through a variety of errors in transcription or 
translation, or simply from genetic mutations in the protein itself, including premature 
stop codons in the amino acid sequence and point mutations in the DNA. For example, 
two different mutations in the protease inhibitor alpha-1 antitrypsin (A1AT) prevent the 
protein from folding correctly and thus result in its degradation [15]. Similarly, a 
phenylalanine deletion at position 508 on the cystic fibrosis transmembrane 
conductance regulator (CFTR) protein causes disease and is degraded once 
recognized by quality control mechanisms [16]. In addition, damage to proteins via heat, 
chemical modifications or oxidative stress can all prevent a protein from reaching its 
native conformation and subjects the protein to degradation by the proteasome [17].
1.1.3 Polypeptide detachment from ribosome
! The ER is a membrane-bound organelle that is continuous with the nuclear 
envelope, and proteins bound for endocytic or secretory  fate are folded here following 
translocation from the ribosome (Figure 1) [18, 19]. Translocation of polypeptides from 
the ribosome generally  occurs via the Sec61 protein channel and is done co-
translationally, meaning that some protein folding is happening concomitant with peptide 
synthesis [20, 21]. A  hydrophobic tag, known as the N-terminal signal sequence, aids in 
the targeting of membrane and soluble proteins and is recognized by the signal 
recognition particle which directs proteins to the ER in eukaryotes [21-23]. The signal 
sequence is not included in the maturation of proteins because it is cleaved from the 
protein by a signal peptidase once inside the ER [23].
3
FIGURE 1: PROTEIN FOLDING IN THE ENDOPLASMIC RETICULUM
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FIGURE 1: Secretory and endocytic proteins  folded in the endoplasmic reticulum (ER) 
are first synthesized by ribosomes. The growing polypeptide is imported into the ER 
and recognized by a variety of folding proteins. Properly folded secretory proteins are 
exported out of the ER and to the Golgi before being sent to their final destination. 
Conversely, improperly folded proteins are recognized in the ER and are integrated 
into a protein quality control mechanism termed ER-associated degradation (ERAD). 
After being recognized as a misfolded protein, resident E3 ubiquitin ligases associated 
with the ER will tag the misfolded protein with ubiquitin and the protein is exported out 
of the ER and into the cytosol for its subsequent degradation by the 26S proteasome.
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1.1.4 Chaperone-assisted protein folding
! Because some polypeptides fold inside the lumen of the ER, there must be 
machinery in place to ensure that the hydrophobic regions do not aggregate together. 
Chaperones are molecules essential for nearly every aspect of protein quality control as 
they prevent protein aggregation and help proteins reach their native conformations 
[24]. Chaperones can belong to any one of several families; arguably  the best known 
chaperones belong to the heat shock protein (Hsp) subfamily, named according to their 
molecular weight ranging from 40-100 kDa [25].
" Belonging to the Hsp70 subfamily of chaperones, Grp78/BiP is one of the first 
chaperones to interact with nascent polypeptides entering the ER [26]. Grp78/BiP was 
found to bind with peptides that contain alternating hydrophobic and aromatic residues 
[27]. Because this is a common sequence found in proteins (it is estimated that most 
proteins contain a hydrophobic interacting region once every 36 residues), Grp78/BiP 
can interact with a wide range of substrates and nearly completely  cover the length of 
the protein [28]. The consistent binding of Grp78/BiP to nascent polypeptides upon 
entering the ER helps ensure the polypeptides move “forward” in their maturation and 
do not progress backwards into the cytosol [29]. 
1.1.5 Asparagine (N)-linked glycan-assisted protein folding
! Besides the innate advantages of glycan-protein association (e.g. mediating 
interactions between cells by covering the surface of mammalian cells), N-linked 
glycans are important players in the molecular recruitment and maturation of proteins in 
the ER [30, 31]. It is estimated that more than 50% of proteins in eukaryotes are 
glycosylated and 1% of all genes in mammals are dedicated to glycosylation [32-34]. 
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This process is believed to help fold and stabilize the maturing protein, as well as 
increase the protein’s solubility [35]. 
" In this process, the asparagine-linked glycan moiety is transferred to the 
glycosylation sequence of a protein (asparagine-X-serine/threonine; the X amino acid 
cannot be proline due to nucleophilic requirements of the reaction [36]) by the 
oligosaccharyltransferase (OST) membrane complex. Best studied in yeast, OST is 
composed of eight subunits: Ost1p, Ost2p, Ost3p/Ost6p, Ost4p, Ost5p, Swp1, Stt3p, 
and Wbp1 [37]. All of these subunits in yeast have mammalian homologs, with the 
exceptions of Ost5p  and Ost4p [38, 39]. In mammals, five subunits are assumed to form 
the core of OST: DAD1, OST48, ribophorin I and II, and STT3A/STT3B [40]. There are a 
minimum of two separate binding sites in the OST complex [41], and it is responsible for 
the generation of the Glc3Man9GlcNAc2 species on the polypeptide [42]. Overall, this 
glycan network in the ER helps maintain the reliability of protein production and folding 
after release from the ribosome.
1.1.6 Regulation of protein folding by calnexin/calreticulin
! Calnexin, and its paralog calreticulin, are crucial regulators of glycoprotein folding. 
These chaperones recognize specific glycan moieties produced by the cleavage of 
glucose residues via glucosidase I/II [43-45]. Importantly, calnexin and calreticulin 
recruit proteins important for catalyzing disulfide bond formation [46-48] as well as 
proteins that mediate calnexin/calreticulin binding to polypeptides allowing time for 
folding to occur in order to help retain proteins in the ER [31]. 
" Calnexin/calreticulin serve as a quality  checkpoint in the protein folding process. 
When glucosidase II removes the final glucose molecule after the glycan is released by 
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calnexin, the protein is allowed to continue through the secretory pathway if it is 
correctly folded [49]. Conversely, if a protein has failed to reach its native conformation it 
can be given another chance to fold correctly, or will be removed from the ER [49]. The 
soluble protein UDP-glucose:glycoprotein glucosyltransferase recognizes improperly or 
incompletely  folded proteins, and tags the protein to enter the calnexin/calreticulin cycle 
again [50].
1.1.7 Selecting proteins to traverse the ER membrane
! New polypeptides are released from ribosomes at a constant pace. Thus, it is 
critical that the ER maintains homeostasis within the organelle by removing the proteins 
that are misfolded or unable to fold. Intuitively, a protein repeating the folding process 
over and over creates an overflow of nascent proteins and not enough secreted, native 
proteins. Cleaving the terminal mannose off glycan moieties prevents the polypeptide 
from trying to refold, and generally serves as the signal for proteins to be removed from 
the ER and degraded by the proteasome [51-53].
" The export of misfolded proteins out of the ER has been a hotly contested topic in 
the field of protein folding and quality control for many years. A few theories have 
emerged that a protein channel is the likely mode of protein export into the cytosol, 
however the proteins that make up this channel are unknown. One potential candidate 
is the Sec61 translocon, which is primarily  responsible for mediating the transport of 
proteins into the ER [54, 55]. Different groups have shown that Sec61 physically 
interacts with substrates in the ER [54, 56, 57]. Expressing mutant Sec61 protein in 
yeast causes an accumulation of protein substrates in the ER [58] or disrupts the 
degradation of misfolded proteins in the ER [59]. Despite these data, the crystal 
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structure of the prokaryotic SecY translocon (homologous to Sec61) demonstrates the 
channel takes the shape of two funnels with the narrow stems facing each other which 
may only be large enough to fit unfolded, extended polypeptides [55, 60], conflicting 
with the potential role of Sec61 as an import and export channel.
" Derlin1 (Der1 in yeast), a four-transmembrane domain protein exposes a small 
region into the cytoplasm [61] and is potentially  another candidate that functions to 
export anomalous proteins out of the ER [62, 63]. When der1 is deleted in yeast, ER 
lumenal protein turnover is absent; however, membrane-bound ER proteins are largely 
unaffected [64, 65]. Mammalian Derlin1 can form large protein complexes in the ER 
membrane [62, 66], thus supporting the premise that this protein functions as a channel 
exporting proteins out of the ER for proteasomal degradation. However, the evidence for 
how proteins are ultimately extracted out of the ER via Sec61 or Derlin1 is still largely 
controversial at best. Future studies in protein export after misfolding are needed to 
make this process more clear.
1.2 Protein ubiquitination
 The process of tagging proteins with ubiquitin is  one of several post-translational 
modifications that can occur, and is the primary method of signaling protein degradation 
by the proteasome. Ubiquitination is a crucial regulator of most cellular pathways and 
relies on several enzymes functioning in a coordinated series of steps (Figure 2). First, 
as an energy dependent process, ATP is expended and free ubiquitin forms a high-
energy intermediate with the catalytic cysteine of an E1 ubiquitin-activating enzyme [67]. 
After being transferred to an E2 ubiquitin-conjugating enzyme, ubiquitin attachment to a 
protein substrate is mediated by an E3 ubiquitin ligase [67]. Ubiquitin is attached to a 
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target protein as a single ubiquitin species or as a polyubiquitin chain conjugated to 
itself via one of seven residues (K6, K11, K27, K29, K33, K48, K63), or as a linear chain 
[68]. The fate of the protein typically depends on the type of polyubiquitin attached to it. 
K48-linked chains target polypeptides  for proteasomal degradation, whereas K63-linked 
chains play functional roles in processes including DNA repair, signal transduction, and 
trafficking [69-73]. In mammals, there are two E1s, dozens of E2s, and hundreds  of 
known E3 ubiquitin ligases [74, 75]. 
1.2.1 Ubiquitin-conjugating enzymes
 As the name would suggest, E2 ubiquitin-conjugating enzymes play an important 
role in the conjugation of ubiquitin to substrates. Members of the ubiquitin-conjugating 
family share a conserved region, termed the ubiquitin-conjugating catalytic (UBC) fold, 
which is responsible for providing binding regions for E1 and E3 proteins, as well as 
activated ubiquitin [76, 77]. Well-characterized in yeast, ubiquitin-conjugating enzymes 
are present in all eukaryotic systems, demonstrating the importance of ubiquitin 
biological systems [78, 79]. Throughout evolution the ubiquitin-conjugating family has 
expanded where higher eukaryotes have more E2s than lower eukaryotes [79]. 
Comparatively, there are 50-75 known [68] human ubiquitin-conjugases compared to 16 
characterized conjugases in yeast [79].
 The degradation of proteins via ER quality control mechanisms in mammals (or 
yeast) depends on the activity of various  ubiquitin-conjugating enzymes: Ube2J2 
(Ubc6), Ube2G2 (Ubc7), Ube2K (Ubc1), Ube2J1 (Ubc6e) [80-83]. Evidence regarding 
structure and sequence similarities with orthologs demonstrates that Ube2G2 is highly 
conserved and underlies its physiological importance in ubiquitination [84]. 
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FIGURE 2: PROCESS OF UBIQUITINATION
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FIGURE 2: The tagging of proteins with ubiquitin is one of several post-translational 
modifications that can occur and is used commonly to label misfolded, toxic, or short-
lived proteins with ubiquitin in order to signal for their proteasomal degradation in 
eukaryotes. In an ATP-dependent manner, ubiquitin is transferred in a series of steps 
from an E1 activating enzyme to an E2 ubiquitin-conjugase before interacting with an 
E3 ubiquitin ligase. Substrates can be tagged with one ubiquitin moiety, or this 
process can repeat itself several times, forming a polyubiquitin chain on the misfolded 
protein. Monoubiquitination generally has non-proteolytic, signaling roles, whereas 
polyubiquitinated substrates can be proteasomal substrates. This process can be 
reversed by a set of proteases known as deubiquitinating enzymes, which can edit the 
length of the polyubiquitin chain or completely remove the ubiquitin chain from the 
protein. 
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1.2.2 ER ubiquitin ligases in protein quality control
 The final step of ubiquitination is carried out by a family of proteins known as E3 
ubiquitin ligases. Two of the most commonly studied E3 ligase families are the RING 
(really interesting new gene) and HECT (homologous to E6-AP carboxyl terminus) 
ligases, which have different modes of action (Figure 3). For HECT ligases, ubiquitin is 
transferred from the ubiquitin-conjugating enzyme to the ligase and lastly to the protein 
substrate. On the other hand, RING ligases act similarly to a scaffold, ushering the 
ubiquitin moiety from the E2 directly to the substrate [86]. RING ligases can function in 
the cytosol (e.g. CHIP) or be membrane-bound entities (e.g. HRD1) [87, 88]. RING 
ligases can function as single proteins  or as  a part of a larger complex. Parkin, a single 
molecule ubiquitin ligase, contains  a recognition motif and RING domain in itself [89]. 
Conversely, large ubiquitin ligase complexes  have several different proteins that share 
the roles of substrate recognition and RING domain catalytic activity, among other roles 
[86].
 In yeast, depending on the location of the misfolded substrate, one of two E3 
RING ligases could be used; the Doa10 ligase complex removes anomalous proteins 
from the cytosolic space, whereas the Hrd1p ligase functions in the ER lumen and 
membrane [90, 91]. The lines for these distinct roles in yeast are blurred, but in humans 
there does seem to be subtle specificity for ligase-substrate interaction. For example, 
HRD1 in humans has  been shown to associate with soluble and membrane-bound 
proteins in the ER [92, 93]. 
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FIGURE 3: E3 UBIQUITIN LIGASES IN UBIQUITINATION
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FIGURE 3: The ubiquitination process has been described (Figure 2), and while the 
roles of E1 activating enzymes remain fairly consistent (only two known E1 enzymes 
in mammals), there are a variety of functions between E2 ubiquitin-conjugases  and E3 
ubiquitin ligases. There are two different types of E3 ubiquitin ligases: RING and 
HECT ligases. There are hundreds of RING ligases compared to only dozens of 
HECT ligases in mammals, and their roles in transferring ubiquitin to misfolded 
substrates differ. For HECT family E3 ubiquitin ligases, ubiquitin is transferred from E1 
to E2 to E3 in a sequential manner prior to labeling the substrate with the ubiquitin 
moiety. Conversely, for RING family ubiquitin ligases, the E3 ligase acts as  a 
scaffolding protein, mediating the transfer of ubiquitin from the E2 ubiquitin-conjugase 
to the substrate protein.
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 In humans, HRD1 and GP78/AMFR are two of the better characterized E3 ligases 
in the ER. Both ligases are homologous to the yeast Hrd1p, but each forms a different 
complex and presumably targets different substrates [92, 94-97]. Various  other E3 
ligases have been implicated through mammalian systems in quality control, but the 
exact function and roles of these ligases remains largely unclear; however they are 
assumed to contribute to the turnover of a limited range of substrates compared to 
HRD1 and GP78/AMFR [98-106]. Currently, some substrate/ligase preference has been 
demonstrated, but delineating these interactions specifically has been a difficult task, 
especially because the exact identifying features of the misfolded protein that are 
recognized by ubiquitin ligases are chiefly unknown [107]. Interestingly, GP78 itself is a 
substrate of HRD1 [108, 109]; therefore, decreased levels of HRD1 leads to increased 
GP78 protein and increased turnover of GP78 specific substrates.
1.2.2.1 HMG-CoA reductase degradation protein 1 (HRD1)
 HRD1 (also known as Synoviolin in mammals) is a 617 amino acid protein (Figure 
4) which includes six transmembrane domains, a catalytic RING domain, and an 
arginine-rich VCP/p97 binding domain near its C-terminus [110-113]. Due to its  innate 
role as a resident E3 ubiquitin ligase in the ER, HRD1 is responsible for essentially 
targeting substrates for proteasomal degradation by tagging them with ubiquitin. HRD1 
was first found to be implicated in the turnover of 3-hydroxy-3-methylglutaryl coenzyme 
A reductase and is named as such [114].
 HRD1 activity is  induced via ER stress and is  implicated in the etiology of 
rheumatoid arthritis  by protecting cells from apoptosis, leading to hyperplasia [115]. 
Besides HMGR and GP78, other reported substrates of HRD1 include misfolded insulin, 
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FIGURE 4: HMG-CoA REDUCTASE DEGRADATION PROTEIN 1 (HRD1)
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FIGURE 4: (A) The 617 amino acid (a.a.) protein HRD1 belongs to the RING family of 
ligases. HRD1 contains six transmembrane domains (TM; blue), a RING ligase region 
necessary for its  catalytic activity (green), and an arginine-rich VCP/p97 binding 
domain (purple) important for mediating the interaction between HRD1 and VCP/p97. 
Additionally, wild type HRD1 contains 4 lysine (K) residues in its non-membrane-
bound region that we mutated into the non-ubiquitinatable amino acid arginine (R) for 
experiments in this  report. The red arrow labels amino acid 241, and an HRD1 
construct containing amino acids 241 to 617 is used for several biochemical, in vitro 
experiments omitting the membrane-bound portion of HRD1. (B) Detailed amino acid 
sequence of HRD1 where the cytoplasmic domain used for in vitro experiments is 
highlighted in red font. The catalytic cysteine residue in the RING domain is 
highlighted in green, and the four lysine resides in the cytosolic region are shown in 
blue. Also shown are the four arginine residues that compose the VCP/p97 binding 
domain of HRD1.
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TCRα, and CD3δ [116-118]. The association of HRD1 with various lectins  such as 
XTP3-B and OS-9, as well as the derlin family of proteins  and Sel1L (a protein 
implicated in the degradation of glycoproteins), is found to form a large, membrane-
bound complex that functions in ERAD [63, 119]. The HRD1 gene is  essential in 
mammals as mouse models have demonstrated that knockout mice are embryonic 
lethal [120]. HRD1 has been shown to interact with at least two different ubiquitin-
conjugases: Ube2G2 and Ube2J1 [96, 118]. Despite this knowledge, the exact role(s) of 
HRD1 in ERAD is not well understood.
1.2.3 Anomalous protein extraction from the ER
 VCP/p97 (known as  Cdc48 in yeast), is  a AAA ATPase with several diverse roles, 
but arguably best known for its  role in ERAD [121-123]. Early work in yeast using 
biochemistry and genetic manipulations found that Cdc48 functioned as a segregase, 
separating ubiquitinated proteins  from the membrane of the ER, as  well as other 
reported roles in mitotic spindle disassembly [124, 125].
 In mammalian systems, VCP/p97, along with cofactors  UFD1 and NPL4, bind 
ubiquitin, thus implicating VCP/p97 in quality control mechanisms, more specifically 
ERAD [126]. Proteins including Erasin, UBXD8, and VIMP function as recruitment 
factors for VCP/p97 towards the location of the misfolded protein in the ER membrane 
and interact with VCP/p97 through each protein’s UBX domain that resembles ubiquitin 
structurally [62, 96, 127, 128]. Interestingly, mammalian HRD1 and GP78 both have 
VCP/p97 binding motifs  [110, 129]. By and large, VCP/p97 is thought to guide misfolded 
substrates to the proteasome after ubiquitination of the substrate has occurred [130, 
131].
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 Some work has attempted to delineate the method by which anomalous proteins 
are exported out of the ER. Cell studies have demonstrated that the removal of 
polypeptides from the ER membrane is  an ATP-driven process [132]. VCP/p97 is 
composed of six subunits that assemble into a hexamer along with two ATPase 
domains. It was noted that a conformational change is perhaps the step that allows 
protein export to proceed from mechanical energy produced by the rotation of the 
hexamer due to the hydrolysis of ATP [133, 134]. Altogether, mediating the extraction of 
ubiquitinated proteins from the ER has been a well documented role of VCP/p97.
 1.2.4 Proteasomal degradation of proteins
 After the misfolded polypeptide has been recognized in the ER, ushered through 
the ER lumen to the membrane, tagged for export out of the ER by ubiquitin, and 
translocated into the cytosol, the last stage of ERAD is protein degradation by the 
proteasome. The 26S proteasome is composed of a 20S catalytic core and one or two 
19S cap particles [135]. Very putative “ubiquitin receptors” RPN10 and RPN13 
recognize substrates in the cytosol that need to be degraded and there are a variety of 
proteins inside the 19S proteasome cap that prepare the substrate to enter the 20S core 
[136, 137]. A set of enzymes known as deubiquitinating enzymes (DUBs; will be 
discussed further in section 1.3) can salvage ubiquitin moieties  by removing the 
polyubiquitin chain from the substrate to reuse. The substrate is  unfolded into a 
polypeptide stretch by ATPases and, once inside the 20S core of the proteasome, the 
polypeptide is proteolytically degraded and released back into the cytosol as small 
peptides that are subsequently cleaved into single amino acids  by endo- or amino-
peptidases [138].     
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1.3 Deubiquitinating enzymes (DUBs) in protein quality control
 The process of ubiquitination is  reversible by a set of enzymes, known as DUBs, 
that control the ubiquitin status of a protein by modifying the isopeptide bond between 
molecules. DUBs function by editing the length of the polyubiquitin chain on the 
substrate itself, or by completely removing the ubiquitin chain [139]. There are roughly 
95 human DUBs encoded in the genome which are divided into five classes  of 
intracellular cysteine or metallo-proteases based on the topology of the catalytic domain 
[140]. Ubiquitin specific proteases (USP; by far the largest family with over 50 proteins 
in humans), Machado-Joseph disease proteases (MJD), ubiquitin C-terminal hydrolase 
(UCH), and Otubain proteases (OTU) are all cysteine proteases (referring to the amino 
acid used in their active site) and JAB1/MPN/Mov34 metallo-enzymes, as the name 
suggests, are metallo-proteases where a conserved cysteine interacts  with a zinc 
residue in the active site. Increased understanding of the function and roles of DUBs 
has led to several new implications of DUBs in diseases, including neurodegenerative 
disease, infectious disease and malignancies [141, 142]. 
1.3.1 Deubiquitinating enzymes in ERAD
 YOD1, a DUB in the Otubain protease class, was one of the first DUBs implicated 
in ERAD and protein extraction from the ER [143]. In this  report, Ernst and colleagues 
hypothesized that in order for the ubiquitin-tagged protein to pass through the VCP/p97 
channel, the polyubiquitin chains must be edited or removed. By expressing the inactive 
form of YOD1, the export of proteins out of the ER is inhibited. Additionally, further work 
demonstrated that the addition of a DUB from the Epstein-Barr virus blocked the 
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degradation of ER proteins, resulting in the accumulation of proteins in the cytosol, 
similar to what one would expect in cells by using proteasome inhibitors [144]. 
 Other DUBs have been implicated in the secretory pathway and in ERAD. For 
example, USP19 has been shown to remove ubiquitin moieties from the ERAD 
substrates TCRα and CFTRΔF508, rescuing them from degradation by the proteasome 
[145]. Conversely, inhibiting the function of the DUBs ataxin-3 or USP13 that function in 
quality control results in the accumulation of misfolded ER substrates [146, 147]. 
Additionally, besides YOD1 as previously mentioned, VCP/p97 has been shown to 
interact with a variety of DUBs in ERAD including ataxin-3, VCPIP1, and USP13 
[146-148]. DUBs associated with VCP/p97 edit ubiquitin chain length of the substrate, 
which has been shown to recycle the protein or conversely, improve proteasomal 
targeting [126, 130]. Interestingly, ataxin-3 has been shown to interact with another 
proteasomal shuttle protein, hHR23 (also known as Rad23) where the presumed 
function is that ataxin-3 deubiquitinates and transfers the substrate to hHR23, while 
keeping the polyubiquitin chain long enough to still be recognized by the proteasome for 
degradation [146].
1.4 Endoplasmic Reticulum-Associated Degradation (ERAD)
 As mentioned, proteins  that fail to reach their native conformations  in the ER 
trigger a quality control mechanism known as endoplasmic reticulum-associated 
degradation, or ERAD, to sort misfolded proteins out of the crowded ER and into the 
cytosol for degradation by the proteasome. It does this in a series  of four seemingly 
simple steps: 1) chaperones in the ER will recognize the misfolded substrate 
distinguishing it from nascent molecules; 2) an E3 ubiquitin ligase in the ER will tag the 
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polypeptide with ubiquitin; 3) the ubiquitin-tagged protein will be exported out of the ER, 
presumably through a protein channel; and, 4) the 26S proteasome will recognize the 
substrate by the polyubiquitin tag and enzymatically degrade the protein, preventing a 
toxic accumulation of immature proteins (Figure 5).
1.4.1 ER stress
 When the capacity of the ER is  reached, but new polypeptides are still being 
imported into the ER for folding, this  is deemed “ER stress” and is  important because  it 
functions as a signaling system that the accumulation of misfolded, aggregated species 
is  imminent. The unfolded protein response (UPR) is the umbrella mechanism under 
which ERAD functions and works  to maintain cellular homeostasis in times of stress. 
Three separate resident ER membrane proteins work as  transducers of UPR signal and 
are activated when BiP/Grp78 dissociates from the signaling peptides in the lumenal 
region and binds to misfolded polypeptides: IRE1, PERK, and ATF6. 
 IRE1, the most conserved of the ER stress transducers, is  found in all eukaryotic 
species [149]. The cytosolic region of IRE1 contains  endoribonuclease activity as well 
as a serine/threonine kinase [150, 151]. The activation of IRE1 results in the 
transcriptional activation of XBP1, a transcription factor responsible for regulating the 
cellular expression of genes during stress [152]. In a similar manner, PERK activation 
results in the translation of another transcription factor, ATF4, which promotes  the 
transcription of chaperones to help alleviate the stress [153]. Lastly, after dissociation 
from BiP/Grp78, ATF6 leaves the ER and is  exported to the Golgi where it is  cleaved by 
proteases in order to enter the nucleus, where it functions to upregulate proteins 
involved in ERAD and protein folding [154].
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FIGURE 5: ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION
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FIGURE 5: Endoplasmic reticulum-associated degradation (ERAD) is a protein quality 
control process in the ER responsible for removing misfolded, short-lived, and toxic 
proteins from the ER lumen. This  prevents  the toxic accumulation of proteins when 
protein folding is taking place, decreasing the likelihood of disease due to inefficient 
folding. ERAD functions in a series of four steps: 1) the misfolded substrate is 
recognized by an E3 ubiquitin ligase in the ER (HRD1 in this scenario); 2) the E3 
ubiquitin ligase will ubiquitinate the protein and a proteasomal shuttle protein (such as 
VCP/p97) will recognize the ubiquitinated substrate; 3) the ubiquitin-tagged protein is 
extracted into the cytosol and is 4) ushered to the proteasome to be enzymatically 
degraded.
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1.4.2 ER stress and disease
 It is becoming more generally accepted that cell and molecular injury due to 
prolonged ER stress plays a major role in the pathophysiology of a variety of diseases, 
notably, but not limited to, malignancies  and neurodegeneration [155]. Despite most 
human diseases being vastly different in the tissues they affect and their clinical 
manifestation, many share a common molecular thread in which protein misfolding is at 
the root of the disease etiology, or is a significant contributor at the very minimum. Some 
of the diseases associated with ER stress are discussed below.
1.4.2.1 ER stress and malignancy
 Tumor cells often invade cellular environments where metabolic or oxidative stress 
conditions impedes the ER’s ability to properly fold proteins [156-159]. Studies have 
identified a high ER stress response from the signal transducers in the ER in various 
cancer types including breast, liver, esophageal, glioblastoma, multiple myeloma, and 
gastrointestinal [160-165]. A fraction of solid tumors have been noted to have genetic 
mutations in IRE1 [166], and many components necessary for efficient protein folding in 
the ER (e.g. BiP) have been demonstrated to be upregulated to levels that correlate 
with disease advancement [167, 168]. Despite knowing many proteins in ERAD are 
implicated in disease progression, it is  still unclear if they inhibit or enhance tumor 
growth in humans. In vivo work in rodent models has demonstrated the role of ER 
protein folding components in both pro- and anti-angiogenic scenarios, as well as 
demonstrated the ability to stall or promote tumor cell growth [169-172].
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1.4.2.2 ER stress and neurodegeneration
 A hallmark of a variety of neurological disorders is the accumulation of protein 
aggregates affecting neurons and neighboring cells [173]. Notable examples of this 
includes the accumulation of tau and amyloid β in Alzheimer’s  disease or Lewy bodies 
(ubiquitinated protein aggregations composed of α-synuclein) in Parkinson’s disease. 
Not all neurodegenerative disorders  share the same pathophysiology in regards to 
protein aggregation. Others are the result of genetic mutations in disease proteins  (as is 
the case in Huntington’s disease (huntingtin)) which contain abnormally expanded 
polyglutamine domains. Additionally, prions have been shown to form protein 
aggregations and have been implicated in the encephalopathies kuru and Creutzfeldt-
Jakob disease [174, 175]. The build-up of misfolded proteins is toxic to neurons  [176], 
and there is growing evidence that neuronal cell aging, oxidative stress, impaired 
protein degradation and genetic mutations all contribute to protein aggregation and ER 
stress, culminating in neurotoxicity and disease [177-179].
1.4.2.3 ER stress and other human diseases
 Several studies have implicated ER stress with cardiovascular disease, notably 
tissue injury from ischemia [180]. The restriction of blood vessels  under ischemic 
conditions causes hypoglycemia and hypoxia. Hypoxia and metabolic stressors cause 
proteins to misfold and leads to subsequent ER stress. After restoration of normal blood 
flow, oxidative stress  in the ER from the ischemic event disturbs proper protein folding. 
Activation of the UPR has also been demonstrated in rodent models and in humans in 
the formation of atherosclerosis [181, 182]. Knowing this, it is  not surprising that some 
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evidence has documented the activation of ER stress in cases of high cholesterol and 
high fatty acid content [183].
 There are roughly one million predicted insulin molecules created every minute by 
human pancreatic β-cells [184]. Due to the high amount of protein turnover, β-cells need 
properly functioning ERs in order to keep glycemic states normal because an 
abnormally low amount of produced insulin in the body causes diabetes. Insulin 
resistance in obesity due to malfunctioning β-cells can lead to ER stress and may 
induce type 2 diabetes [185]. Similarly, inflammation because of autoimmunity in type 1 
diabetes causes the remaining β-cells  to over-produce insulin [186]. These events 
cause a vicious circle of consistently high ER stress levels, leading to diabetes.
1.5 Concluding remarks 
 Through a variety of biochemical, cellular, and genetic assays, many central 
components of ERAD have been characterized and described. It is  clear that ERAD is 
essential for the regulation of many aspects of cellular biology including protein folding, 
ubiquitin-dependent degradation, protein transport, and regulation of metabolism. 
Pathogens attempt to exploit this system in order to disrupt cellular homeostasis and 
cause disease. ERAD is an essential component of cellular biology and is a critical 
moderator for the delicate balance between protein folding and protein degradation. It 
was the goal of this project to understand how components of ERAD collaborate in 
normal and disease states in order to yield different outcomes. 
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CHAPTER 2: MATERIALS AND METHODS
2.1 Antibodies
 The following primary antibodies were used for western blot analysis  throughout 
the course of this  dissertation: rabbit, polyclonal anti-Ubiquitin (1:500; Dako; Carpinteria, 
CA); rabbit, polyclonal anti-HRD1/SYVN1 (1:1,000; Sigma-Aldrich; St. Louis, MO); 
rabbit, polyclonal anti-HA (Y11) (1:500; Santa Cruz; Dallas, TX); mouse, monoclonal 
anti-V5 (1:5,000; Invitrogen; Carlsbad, CA); mouse, monoclonal anti-APP, clone 22c11 
(1:1,000; EMD Millipore; Billerica, MA); rabbit, polyclonal anti-GFP (1:1,000; Santa Cruz; 
Dallas, TX); rabbit, polyclonal USP25 (1:4,000; previously described [187, 188]); mouse, 
monoclonal anti-c-Myc (9e10) (1:250; Santa Cruz; Dallas, TX); mouse, monoclonal anti-
Ube2J1 (1:500; Origene; Rockville, MD); rabbit, polyclonal anti-Ube2G2 (1:500; 
Origene; Rockville, MD); rabbit, monoclonal anti-K48-linkage Specific Polyubiquitin 
(1:1,000; Cell Signaling; Danvers, MA) [189]; rabbit, polyclonal anti-VCP (1:1,000; Cell 
Signaling; Danvers, MA); rabbit, monoclonal anti-K63-linkage Specific Polyubiquitin 
(1:1,000; Cell Signaling; Danvers, MA) [190]; mouse, monoclonal anti-GAPDH (1:500; 
EMD Millipore; Billerica, MA); mouse, monoclonal anti-Tubulin (1:20,000; Sigma-Aldrich; 
St. Louis, MO); mouse, monoclonal anti-KDEL (1:500; Enzo Life Sciences; Ann Arbor, 
MI); mouse, monoclonal anti-E4B (1:500; BD Biosciences; San Jose, CA); rabbit, 
polyclonal anti-GP78/AMFR (1:1,000; Cell Signaling; Danvers, MA). Peroxidase-
conjugated mouse and rabbit secondary antibodies (Jackson Immunoresearch; West 
Grove, PA) were used at 1:5,000 concentration.
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2.2 Biochemical in vitro reactions
 Bacterial cultures using BL21 competent cells were used for recombinant protein 
production as previously described [191-194]. Biochemical in vitro reaction procedures 
have been described before [192, 193, 195]. Briefly, 1X kinase buffer (0.2 mM DTT, 50 
mM Tris pH 7.5, 50 mM KCl) was incubated with 1 µM of recombinant HRD1 protein 
containing only the RING domain (both lumenal and transmembrane domains were 
excluded; Figure 4) at 37°C. Additionally, 0.3 µM of recombinant E1 protein (Boston 
Biochem; Cambridge, MA), 1 µM of E2 ubiquitin-conjugating enzymes Ube2G2, 
Ube2J1, UbcH5C, Ube2W (Boston Biochem; Cambridge, MA), 60 µM wild type or 
lysine-specific mutant ubiquitin (Boston Biochem; Cambridge, MA), and 5 mM 
MgCl2/5mM ATP were incubated with 1X kinase buffer and recombinant E3 ligase. For 
reactions using the deubiquitinating enzyme ataxin-3, 1 µM was added to the reaction 
mixture prior to the addition of ATP or after quenching ubiquitination reaction with 
excess EDTA. At noted time points, aliquots were taken from each reaction and 
supplemented with 6% boiled SDS prior to being loaded onto SDS-PAGE gels.
2.3 DNA constructs
 All HRD1 DNA constructs  used for mammalian cell expression (wild type, inactive 
[CA], AARA, K-R) were expressed in pcDNA3.1 (Life Technologies; Carlsbad, CA). HA-
tagged ubiquitin for mammalian cell expression was in pRK5 and was a kind gift from 
Dr. Ted Dawson (Johns Hopkins University). Other DNA constructs used have been 
described before [118, 188, 196-200]. HRD1 DNA constructs were mutated (AARA, K-
R) using the QuikChange mutagenesis kit (Agilent; Santa Clara, CA). Small interfering 
RNA (siRNA) was used to perform knockdowns in cells. Three different siRNA 
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constructs  for Ube2J1 (catalog numbers s28177, s28178, s28179) and Ube2G2 
(catalog numbers s14583, s14584, s14585) as well as  a scrambled negative control 
were acquired (Life Technologies; Carlsbad, CA). Seven USP25 shRNA constructs  were 
purchased from Open Biosystems (Lafayette, CO) (V2LHS_63867, V2LHS_63830, 
V2LHS_63903, V2LHS_63904, V2LHS_63902, V2LHS_5201, V2LHS_310311). For 
bacterial expression, HRD1 and ataxin-3 were in pET21a vector. 
2.4 Immunofluorescence
 Immunofluorescence was performed as  previously described [191]. 4% 
paraformaldehyde in PBS was used to fix cells for 20 minutes before rinsing thrice with 
PBT (PBS, 0.1% Triton X-100). After rinsing, cells were blocked for one hour in 5% 
normal goat serum in PBT. Primary antibody (rabbit, polyclonal anti-20S (Affiniti; Exeter, 
UK) and mouse, monoclonal anti-FLAG (Sigma-Aldrich; St. Louis, MO) both used at 
1:500 concentration) was applied overnight. Fluorescent secondary antibodies (1:1,000; 
Jackson Immunoresearch; West Grove, PA) were applied for two hours. Images were 
acquired using an oil immersion lens (100X).
2.5 Immunopurifications
 Immunopurifications were performed as have been previously detailed [191-193, 
201]. Briefly, transfected mammalian cells were harvested and pelleted in ice-cold PBS. 
Pellets were lysed with NETN lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% 
NP-40) supplemented with complete protease inhibitor cocktail (Sigma-Aldrich; St. 
Louis, MO). Following lysis, tagged protein was immunoprecipitated using agarose 
beads conjugated to the epitope tag of interest (Sigma-Aldrich; St. Louis, MO) at 4°C for 
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six hours. After the immunopurification, complexes were rinsed thrice with NETN plus 
protease inhibitor, and subsequently eluted via 2% SDS and boiling.
 For stringent immunopurifications, cells were lysed in RIPA lysis  buffer (150 mM 
NaCl, 50 mM Tris, 0.1% SDS, 1% NP-40, 0.5% deoxycholic acid, pH 7.4) supplemented 
with protease inhibitor cocktail (Sigma-Aldrich; St. Louis, MO). Following lysis, cells 
were denatured for 30 minutes  at room temperature using 1% final SDS and renatured 
in 4.5% final Triton X-100 for 30 minutes. Cells  were then immunopurified with bead-
bound antibodies (Sigma-Aldrich; St. Louis, MO) and rinsed 5-8 times with RIPA lysis 
buffer supplemented with protease inhibitor cocktail before elution by 2% SDS.
2.6 Mammalian cell culture
 Human Embryonic Kidney (HEK)-293, HEK-293T, and HeLa (cervical epithelial 
adenocarcinoma) cells  used for mammalian cell transfection were purchased from 
American Type Culture Collection (ATCC; Mannassas, VA). Each cell line was cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) (ThermoFisher Scientific; Waltham, 
MA). DMEM was supplemented with 10% fetal bovine serum (HyClone Laboratories; 
Logan, UT), 500 µg/ml streptomycin (Invitrogen; Carlsbad, CA) and 100 units/ml 
penicillin (Invitrogen; Carlsbad, CA). Cells were grown at 37°C in 5% CO2 and were 
transiently transfected with DNA plasmids after reaching ~75% confluency using 
Lipofectamine LTX (Invitrogen; Carlsbad, CA) according to the manufacturer’s 
suggested protocol. siRNAs, shRNAs, and additional DNA plasmids were transfected 
using Lipofectamine 3000 or Lipofectamine RNAiMAX (Invitrogen; Carlsbad, CA) per 
the manufacturer’s  instructions. After 48 hours, transfected cells were harvested in 2% 
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boiling SDS buffer (2% SDS, 10% glycerol, 100 mM DTT, 50 mM Tris  pH 6.8) and 
before being loaded onto SDS-PAGE gels, lysates were boiled for 10 minutes. 
 To mimic endoplasmic reticulum stress conditions, non-transfected HeLa cells 
were grown to 80% confluency and treated with varying concentrations of DTT for 6 
hours prior to harvesting. For heat shock, non-transfected HeLa cells were grown at 
37°C in 5% CO2 overnight, and subsequently transferred to 42°C in 5% CO2 for 1-2 
hours to induce stress  [202] before harvesting. The protein concentration of each lysate 
was determined prior to western blotting by the BCA Protein Assay (ThermoFisher 
Scientific; Waltham, MA).
 Breast cancer cell lysates  were a kind gift from Dr. Julie Boerner (Karmanos 
Cancer Institute) and were not cultured in the Todi laboratory. All lysates were measured 
at 50 µg by the BCA Protein Assay (ThermoFisher Scientific; Waltham, MA).
2.7 Mouse tissue homogenization
 The snap-frozen tissues from FVB/N male mice were generously gifted to us by 
Dr. Izabela Podgorski (Wayne State University School of Medicine). The Todi laboratory 
did not have any role in the initial designed use of the mice. Original experiments using 
the mice and the collection of the samples  gifted to us were performed by the Podgorski 
laboratory and were done in accordance with their approved protocol from the Wayne 
State University Animal Investigation Committee as well as  in accordance with National 
Institutes of Health guidelines. To analyze the expression of various ERAD components, 
snap-frozen tissue samples were pulverized and homogenized with RIPA buffer 
supplemented with complete protease inhibitor cocktail (Sigma-Aldrich; St. Louis, MO). 
After lysis, samples were briefly sonicated and centrifugated for 15 minutes at 13,000 x 
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G at 4°C. BCA Protein Assay (ThermoFisher Scientific; Waltham, MA) was used to 
determine the protein concentration of each tissue sample prior to loading onto SDS-
PAGE gels.
2.8 PCR-based analyses  
 TRIzol reagent (Invitrogen; Carlsbad, CA) was used to extract total RNA from cells. 
TURBO DNAse (Ambion; Carlsbad, CA) was used after RNA isolation to eliminate any 
potential confounding DNA contamination. For quantitative RT-PCR, total RNA was 
extracted using TRIzol and treated with TURBO DNAse (Ambion; Carlsbad, CA) to 
eliminate trace DNA. The High Capacity Kit (Applied Biosciences; Carlsbad, CA) was 
used to perform reverse transcription and samples were quantified using fast SYBR 
Green (Applied Biosciences; Carlsbad, CA) with the PlusOne real-time quantitative 
system (Applied Biosciences; Carlsbad, CA). Primer sequences are as follows and are 
human (h) constructs:
Table 1: PCR primer sequences
Primer Name Sequence (5’ - 3’)
h-HRD1-Forward CGCATTGTCTCTCTTATGTTCCTC
h-HRD1-Reverse GTAGAGCATGTACACAGCCTTGTT
h-Ube2G2-Forward CCACTTGATTACCCGTTAAGTCC
h-Ube2G2-Reverse ACAGCAGGATCTTCTCCACACT
h-Ube2J1-Forward GAATGGCACTTCACGGTTAGAG
h-Ube2J1-Reverse GCCTGAGATGCTCAAACAGATT
h-Ube2W-Forward GTGGATTGTAGACATGGAAGGTG
h-Ube2W-Reverse GGACCAGTCTTCTGTTAGAATGGA
h-IRE1-Forward GGATTTTTGGAAGTACCAGCAC
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Table 1: PCR primer sequences
Primer Name Sequence (5’ - 3’)
h-IRE1-Reverse GTATACAGGCTGCCATCATTAGC
h-PERK-Forward GAACCAGACGATGAGACAGAGTT
h-PERK-Reverse CCCAAATACCTCTGGTTTGCTA
h-GAPDH-Forward GCTCAGACACCATGGGGAAGGT
h-GAPDH-Reverse GTGGTGCAGGAGGCATTGCTGA
2.9 Proteasomal inhibition
 Cells  used for mammalian cell culture were grown to transfection confluency per 
the manufacturer’s suggested protocol. Forty-eight hours  post-transfection, cells were 
treated with 15 µM MG132 (AG Scientific; San Diego, CA) for 0-6 hours prior to 
harvesting cells by boiling SDS/DTT lysis  buffer. Cell lysates were electrophoresed for 
western blotting analysis.
2.10 Pulse-chase analyses
 Cells  were grown to 70-75% confluency and transiently transfected with prepared 
DNA constructs. After 48 hours, cells were treated with 75 µg/ml cycloheximide (AG 
Scientific; San Diego, CA) dissolved in pure water, or with vehicle control for up to 6 
hours. After treatment, cells were harvested using boiling SDS lysis  buffer and loaded 
onto SDS-PAGE for western blotting.
2.11 Western blot analyses, quantification, and statistical analyses
 For all SDS-PAGE, 10%, 15% or 4-20% gradient gels were used, and transferred 
on PVDF membranes (Bio-Rad; Hercules, CA). Western blots were imaged using the 
VersaDoc 5000MP (Bio-Rad; Hercules, CA) and quantified using Quantity One software 
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(Bio-Rad; Hercules, CA) as previously described [203]. Student T-tests were used for 
statistical analyses. 
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CHAPTER 3 - HRD1 AND ASSOCIATED UBIQUITIN-CONJUGASES IN ERAD
3.1 General introduction and hypothesis
 ERAD is a critical component of protein quality control in the ER responsible for 
maintaining homeostasis of the cellular machinery [107, 204]. Central to ERAD’s ability 
to recognize and remove aberrant polypeptides from the ER lumen is the function of E3 
ubiquitin ligases. HRD1 is a resident E3 ubiquitin ligase on the ER membrane and is 
primarily responsible for the recognition of misfolded or toxic proteins inside the ER. 
HRD1 in mammals has  been reported to interact with at least two different E2 ubiquitin-
conjugases: Ube2G2 and Ube2J1 [96, 118]. Because ERAD is found in a wide range of 
tissues and systems, and aberrant ERAD, is implicated in a number of physiologically-
distinct diseases, we hypothesized that different types of ERAD operate in different 
tissue and in normal and disease states. Longer term, we wanted to understand how 
ERAD components interact to yield different outcomes (i.e. normal versus disease 
states). We examined the expression of HRD1 and the ubiquitin-conjugases Ube2G2 
and Ube2J1 in mouse tissue.
3.2 HRD1 is expressed with ubiquitin-conjugases in mouse tissue
 We used six different tissue types, each with varying physiological function in vivo, 
to examine the expression of HRD1 and other ERAD proteins with which it is known to 
interact. HRD1 is expressed abundantly both in the kidney and spleen, and HRD1 
expression is  clear in the brain, albeit not as robustly as in the kidney or spleen (Figure 
6). Additionally, endogenous  HRD1 cannot be detected in the skeletal muscle tissue or 
the heart, but is  slightly visible in the lung (Figure 6). In mouse tissues, the anti-HRD1 
antibody in the laboratory
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FIGURE 6: HRD1 IS EXPRESSED WITH DIFFERENT UBIQUITIN-CONJUGASES IN 
MOUSE TISSUE
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FIGURE 6: HRD1, Ube2G2 and Ube2J1 expression in different mouse organs. Male, 
FVB/N mouse tissue was homogenized in RIPA lysis buffer in the presence of a 
protease inhibitor cocktail (Materials and Methods). 100 µg of total protein was loaded 
in each lane as determined by BCA protein assay. Two different loading controls (anti-
GAPDH, anti-Tubulin) are shown to demonstrate variability among the different 
samples in proteins used for loading.
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FIGURE 7: PROTEIN CODING ISOFORMS OF MOUSE HRD1 (PREDICTED)
mSyvn-5         MFRTAVMMAASLALTGAVVAHAYYLKHQFYPTVVYLTKSSPSMAVLYIQAFVLVFLLGKV 60
mSyvn-6         MFRTAVMMAASLALTGAVVAHAYYLKHQFYPTVVYLTKSSPSMAVLYIQAFVLVFLLGKV 60
mSyvn-2         MFRTAVMMAASLALTGAVVAHAYYLKHQFYPTVVYLTKSSPSMAVLYIQAFVLVFLLGKV 60
mSyvn-1         MFRTAVMMAASLALTGAVVAHAYYLKHQFYPTVVYLTKSSPSMAVLYIQAFVLVFLLGKV 60
mSyvn-4         MFRTAVMMAASLALTGAVVAHAYYLKHQFYPTVVYLTKSSPSMAVLYIQAFVLVFLLGKV 60
                ************************************************************
mSyvn-5         MGKVFFGQLRAAEMEHLLERSWYAVTETCLAFTVFRDDFSPRFVALFTLLLFLKCFHWLA 120
mSyvn-6         MGKVFFGQLRAAEMEHLLERSWYAVTETCLAFTVFRDDFSPRFVALFTLLLFLKCFHWLA 120
mSyvn-2         MGKVFFGQLRAAEMEHLLERSWYAVTETCLAFTVFRDDFSPRFVALFTLLLFLKCFHWLA 120
mSyvn-1         MGKVFFGQLRAAEMEHLLERSWYAVTETCLAFTVFRDDFSPRFVALFTLLLFLKCFHWLA 120
mSyvn-4         MGKVFFGQLRAAEMEHLLERSWYAVTETCLAFTVFRDDFSPRFVALFTLLLFLKCFHWLA 120
                ************************************************************
mSyvn-5         EDRVDFME——————————RSPN—————————ISWLFHCRIV 142
mSyvn-6         EDRVDFME——————————RSPN—————————ISWLFHCRIV 142
mSyvn-2         EDRVDFME——————————RSPN—————————ISWLFHCRIV 142
mSyvn-1         EDRVDFME——————————RSPN—————————ISWLFHCRIV 142
mSyvn-4         EDRVDFYAILMTMVLTIFIKYVLHSVDLQSENPWDNKAVYMLYTELFTGFIKVLLYMAFM 180
                ******                      :* *                  *. *::  ::
mSyvn-5         SLMFLLGILDFLFVSHAYHSILTRGASVQLVFGFEYAILMTMVLTIFIKYVLHSVDLQSE 202
mSyvn-6         SLMFLLGILDFLFVSHAY————————————————————— 160
mSyvn-2         SLMFLLGILDFLFVSHAYHSILTRGASVQLVFGFEYAILMTMVLTIFIKYVLHSVDLQSE 202
mSyvn-1         SLMFLLGILDFLFVSHAYHSILTRGASVQLVFGFEYAILMTMVLTIFIKYVLHSVDLQSE 202
mSyvn-4         TIMIKVHTFPLFAIRPMYLAMRQFKKAVTDAIMSRRAIRNMNTLYPDATPEELQAMDNVC 240
                ::*: :  : :: :   *                                          
mSyvn-5         NPWDNKAVYMLYTELFTGFIKVLLYMAFMTIMIKVHTFPLFAIRPMYLAMRQFKKAVTDA 262
mSyvn-6         ——————————————————————————————
mSyvn-2         NPWDNKAVYMLYTELFTGFIKVLLYMAFMTIMIKVHTFPLFAIRPMYLAMRQFKKAVTDA 262
mSyvn-1         NPWDNKAVYMLYTELFTGFIKVLLYMAFMTIMIKVHTFPLFAIRPMYLAMRQFKKAVTDA 262
mSyvn-4         IICREEMVTGAKRLPCNHIFHTSCLRSWFQRQQTCPTCRMDVLRASLPAQSPPPPEPADQ 300
                                                                            
mSyvn-5         IMSRRAIRNMNTLYPDATPEELQAMDNVCIICREEMVTGAKRLPCNHIFHTSCLRSWFQR 322
mSyvn-6         ——————————————————————————————
mSyvn-2         IMSRRAIRNMNTLYPDATPEELQAMDNVCIICREEMVTGAKRLPCNHIFHTSCLRSWFQR 322
mSyvn-1         IMSRRAIRNMNTLYPDATPEELQAMDNVCIICREEMVTGAKRLPCNHIFHTSCLRSWFQR 322
mSyvn-4         GPPPAPHPQPLLPQPPNFPQGLLPPFPPGMFPLWPPMGPFPPVPPPPSSGEAAAPPPTST 360
                                                                            
mSyvn-5         QQTCPTCRMDVLRASLPAQSPPPPEPADQGPPPAPHPQPLLPQPPNFPQGLLPPFPPGMF 382
mSyvn-6         ——————————————————————————————
mSyvn-2         QQTCPTCRMDVLRASLPAQSPPPPEPADQGPPPAPHPQPLLPQPPNFPQGLLPPFPPGMF 382
mSyvn-1         QQTCPTCRMDVLRASLPAQSPPPPEPADQGPPPAPHPQPLLPQPPNFPQGLLPPFPPGMF 382
mSyvn-4         AVSRPSGAATTTAAGTSTSAPAPGSVPGPEAGPAPGFPFPPPWMGMPLPPPFAFPPMPVP 420
                                                                            
mSyvn-5         PLWPPMGPFPPVPPPPSSGEAAAPPPTSTAVSRPSGAATTTAAGTSTSAPAPGSVPGPEA 442
mSyvn-6         ——————————————————————————————
mSyvn-2         PLWPPMGPFPPVPPPPSSGEAAAPPPTSTAVSRPSGAATTTAAGTSTSAPAPGSVPGPEA 442
mSyvn-1         PLWPPMGPFPPVPPPPSSGEAAAPPPTSTAVSRPSGAATTTAAGTSTSAPAPGSVPGPEA 442
mSyvn-4         PAGFAGLTPEELRALEGHERQHLEARLQSLRNIHTLLDAAMLQINQYLTVLASLGPPRPA 480
                                                                            
mSyvn-5         GPAPGFPFPPPWMGMPLPPPFAFPPMPVPPAGFAGLTPEELRALEGHERQHLEARLQSLR 502
mSyvn-6         ——————————————————————————————
mSyvn-2         GPAPGFPFPPPWMGMPLPPPFAFPPMPVPPAGFAGLTPEELRALEGHERQHLEARLQSLR 502
mSyvn-1         GPAPGFPFPPPWMGMPLPPPFAFPPMPVPPAGFAGLTPEELRALEGHERQHLEARLQSLR 502
mSyvn-4         TSVNPTEETASTVVSAAPSTSAPSSEAPTPSPGASPPIPEAEKPPAPESVGIVEELPEDG 540
                                                                            
mSyvn-5         NIHTLLDAAMLQINQYLTVLASLGPPRPATSVNPTEETASTVVSAAPSTSAPSSEAPTPS 562
mSyvn-6         ——————————————————————————————
mSyvn-2         NIHTLLDAAMLQINQYLTVLASLGPPRPATSVNPTEETASTVVSAAPSTSAPSSEAPTPS 562
mSyvn-1         NIHTLLDAAMLQINQYLTVLASLGPPRPATSVNPTEETASTVVSAAPSTSAPSSEAPTPS 562
mSyvn-4         EPDAAELRRRRLQKLESPVAH———————————————————- 561
                                                                            
mSyvn-5         PGASPPIPEAEKPPVGIVEELPEDGEPDAAELRRRRLQKLESPVAH—— 608
mSyvn-6         —————————————————————————
mSyvn-2         PGASPPIPEAEKPPAPESVGIVEELPEDGEPDAAELRRRRLQKLESPVAH 612
mSyvn-1         PGASPPIPEAEKPPAPESVGIVEELPEDGEPDAAELRRRRLQKLESPVAH 612
mSyvn-4         —————————————————————————
Predicted 
Molecular Weight
~67 kDa
~19 kDa
~67 kDa
~67 kDa
~62 kDa
FIGURE 7: Hrd1 genomic sequences were aligned using the ClustalW2 multiple 
sequence alignment tool. The VCP/p97 binding domain of HRD1 is highlighted in red 
font. The predicted molecular weights of each protein coding isoform are shown in 
blue as determined by ProtParam.
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detects  two distinct bands. Because there are at least five protein coding isoforms of 
hrd1 in mice [205], the endogenous  bands detected by the antibody may represent 
different isoforms of HRD1. Using ProtParam, an online tool which computes physical 
and chemical components  of a protein, the two bands we observe in these tissues could 
be isoforms 1 and 5 (Figure 7). Both isoforms 1 and 5 contain the arginine-rich VCP/p97 
binding domain. 
 We know that Ube2G2 and Ube2J1 functionally interact with HRD1 [96, 118], so 
we examined the expression of these two ubiquitin-conjugases in the same mouse 
tissue that we found HRD1 to be expressed (Figure 6). Interestingly we found that 
HRD1 and Ube2G2 are expressed in different tissue samples than HRD1 and Ube2J1. 
For example, HRD1 and Ube2G2 are expressed together in the kidney, but not as much 
in the brain (Figure 6). Conversely, HRD1 and Ube2J1 are both expressed in the brain, 
but not in the kidney (Figure 6). 
3.3 HRD1 is expressed with ubiquitin-conjugases in breast cancer cell lines
 Examining the expression of ERAD components in mouse tissue led us to 
consider that indeed HRD1 may collaborate with different ubiquitin-conjugases 
depending on the tissue in which the ER stress is occurring. We wondered whether 
HRD1 and the ubiquitin-conjugases Ube2G2 and Ube2J1 demonstrate variable 
expression patterns in different cancer cell lines, which would suggest the collaboration 
of ERAD components depends on the tissue and disease type.
3.3.1 Invasive ductal carcinoma
 The breast cancer cell lysates  that were used in this  study are all subtypes of a 
breast cancer diagnosis of invasive ductal carcinoma (IDC) which, according to the 
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National Cancer Institute, is  characterized by cancer cells breaking through the basal 
membrane of the ductal epithelium and invading the surrounding lymphatic and tissue 
systems. IDC is  further characterized by specific properties of the tumor itself in order to 
gauge prognosis and determine an appropriate treatment plan. Most notably, the 
hormone status of the tumor is an important prognostic indicator for the patient because 
the molecular profile of the tumor sometimes determines the treatment plan (other than 
tumor morphology). The presence of two different hormone receptors - estrogen 
receptor and progesterone receptor - are commonly screened for variations in their 
molecular profile [206]. In addition to these hormone receptors, a growth factor receptor 
known as human epidermal growth factor receptor 2 (HER2) is commonly amplified and 
included in the molecular screen [206]. However, the most aggressive subtype is the 
triple-negative, basal-like breast cancer where aberrant tumor cells  are estrogen 
receptor and progesterone receptor negative, and are lacking enrichment by HER2 
[206]. These patients  suffer from a poor prognosis and their cancer is extremely 
invasive and aggressive.
3.3.2 ERAD protein expression in breast cancer cell lines
 We acquired cell lysates from three different molecular subtypes of human breast 
cancer (estrogen receptor positive, HER2 positive, and the basal-like triple-negative) 
and we examined this panel of cell lines for the expression of HRD1 and the ubiquitin 
conjugases Ube2G2 and Ube2J1 (Figure 8). Tumor cell lines positive for estrogen 
receptor each express HRD1 abundantly, although the ubiquitin-conjugase Ube2G2 
was expressed at near equal level in each sample. Conversely, Ube2J1 is highly 
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FIGURE 8: PROTEIN EXPRESSION OF HRD1 AND OTHER ERAD COMPONENTS 
IN BREAST CANCER CELL LYSATES
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FIGURE 8: HRD1, Ube2G2, and Ube2J1 expression in three different subtypes of 
breast cancer: estrogen receptor positive (red), HER2 positive (blue), and triple 
negative (purple). Lysates were loaded at 50 µg/lane concentrations as determined by 
BCA protein assay.  
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expressed in the SUM44 cell line, but not as readily expressed in the MCF7 cell line 
which may reflect more specific differences in the characterization of these cell lines. 
 In the HER2 positive cell lines, HRD1 protein is  expressed across the board at 
near equal levels with the exception of two cell lines; SUM52 and SUM225 have 
diametrically opposite protein expression levels of HRD1. The SUM225 line abundantly 
expresses HRD1 protein whereas the SUM52 cell line does not contain endogenous 
HRD1. This suggests that perhaps an ubiquitin ligase other than HRD1 is responsible 
for E3 activity in this type of breast cancer (e.g. GP78, perhaps), or perhaps the 
attempts at homeostasis in this disease model uses a different mechanism of 
degradation that bypasses HRD1. All HER2 positive cell lines tested expressed both 
Ube2G2 and Ube2J1 protein, suggesting that these ubiquitin-conjugases are involved in 
maintaining proper protein folding to degradation rates.
 The most aggressive disease in vivo, triple-negative cell lines, mostly all express 
HRD1, Ube2G2 and Ube2J1 protein at very similar levels, although a few cell lines  have 
interesting characteristics. The BT549 cell line abundantly expresses HRD1 protein, 
although the endogenous  levels of Ube2G2 and Ube2J1 are low suggesting that HRD1 
may cooperate with unidentified ubiquitin-conjugases in breast cancer with this specific 
molecular profile. SUM159 breast cancer cells do not express HRD1 protein at the 
endogenous level, but highly express Ube2J1 indicating that this ubiquitin-conjugase 
perhaps functions with a different ubiquitin ligase in quality control. Lastly, in MDA-
MB-468 cells, HRD1 and both Ube2G2 and Ube2J1 are all expressed at high 
endogenous protein levels  suggesting that these proteins work together in this tumor 
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cell line in ERAD, but does not rule out the possibility that other ligases and conjugases 
could be working together with HRD1, Ube2G2 and Ube2J1.
3.4 Dynamic regulation of ERAD components during stress in cultured cells
 HRD1 is divergently expressed along with ubiquitin-conjugases Ube2G2 and 
Ube2J1 in different tissues and this co-presence also varies based on the molecular 
profile of disease in breast cancer (Figures 6, 8). We wondered if different inducers  of 
cellular stress cause dynamic expression of ERAD components in cells. Here, we 
examined HRD1 and the ubiquitin-conjugases Ube2G2, Ube2J1, and Ube2W under 
cultured cell stress conditions. Ube2W is an E2 ubiquitin-conjugase that interacts with 
the E3 HECT family ligase CHIP, and ubiquitinates substrates at the N-terminus [195, 
207]. Because CHIP is implicated in protein quality control by targeting substrates for 
proteasomal degradation, we wondered whether Ube2W collaborates with HRD1 in 
ERAD as well. Unfortunately, due to the lack of a reliable antibody available for Ube2W, 
we were unable to examine the endogenous  levels of this particular ubiquitin-conjugase 
in tissue and breast cancer cell lines.
 Cellular stress in non-transfected HeLa cells was induced using a pharmacological 
ER stress inducer (DTT) as well as a physiological ER stress inducer (heat shock). The 
reducing agent DTT prevents disulfide-bond formation and therefore is  a pan-inducer of 
cellular stress by causing the accumulation of proteins in both the ER lumen and in the 
cytoplasm. Physiologically, the increased synthesis of the heat shock protein family of 
chaperones is a generic indicator of induced cellular stress.
  We examined the mRNA and protein levels of HRD1, and the ubiquitin-conjugases 
Ube2G2, Ube2J1, and Ube2W after the induction of ER stress by DTT and heat shock 
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using non-transfected HeLa cells in order to determine if certain collaborations between 
HRD1 and the ubiquitin-conjugases with which it interacts take place under different 
stress conditions (Figure 9). The transcript levels of all four ERAD components varied 
under pharmacological (Figure 9A) and physiological (Figure 9B) stress. Despite the 
absence of a clear dose-dependent increase at the mRNA level for either stressor, 
HRD1 and its collaborating ubiquitin-conjugases are dynamically regulated at the 
expression level in response to ER stress. 
 Next, we examined the mRNA level of ER stress sensors  IRE1 and PERK and 
noticed a clear induction of the PERK stress signal with both the DTT treatment and 
heat shock, as well as an increase at the protein level for Hsp70, a heat shock protein 
chaperone that is induced under environmental stress conditions (Figure 9B). 
 The expression of Ube2G2 and Ube2J1 at the protein level does not match what is 
demonstrated at the mRNA level, and although somewhat discouraging, perhaps 
indicates that the turnover of each protein is different in a stressor-specific basis. 
Together, these data (Figures 6, 8 and 9) suggest that HRD1 collaborates with different 
ubiquitin-conjugases in ERAD depending on the tissue where the injury is located, the 
type of disease caused by the overwhelming stress, and what kind of stress is  causing 
the accumulation of proteins.
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FIGURE 9: COLLABORATION OF ERAD COMPONENTS UNDER 
PHARMACOLOGICAL AND PHYSIOLOGICAL ER STRESS
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FIGURE 9: HRD1 and the ubiquitin-conjugases Ube2G2, Ube2J1, and Ube2W 
mRNA and protein expression under induced ER stress conditions. Cell stress was 
induced in HeLa cells using varying concentrations of DTT or placed under heat shock 
for 1-2 hours. DTT treatment lasted for 6 hours before cells were harvested. Heat 
shock conditions were mimicked by placing cells in 42°C  incubator with 5% CO2. IRE1 
and PERK are ER stress reporters. 
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CHAPTER 4 - HRD1 FORMS DIFFERENT POLYUBIQUITIN CHAINS IN VITRO
4.1 General introduction and hypothesis
 Over the years, significant work has been done examining the ERAD pathway and 
the role(s) of HRD1 in it. Besides being a major player in the ERAD pathway due to its 
innate ligase function, HRD1 is one of the better characterized mammalian ubiquitin 
ligases. Additionally, as previously discussed, HRD1 is an essential gene in mammals 
as it has been demonstrated that HRD1 null mice are embryonic lethal [120]. Despite 
being known to interact with Ube2G2 and Ube2J1, the role(s) of HRD1 in ERAD are still 
largely unclear. In order to better understand how ERAD works in normal and disease 
states, it is  essential to understand how the proteins implicated in this  pathway function 
together. Several unresolved questions remain regarding HRD1’s  role in the ERAD 
pathway. We hypothesized that HRD1 forms different ubiquitin-ubiquitin linkages in 
vitro with different ubiquitin-conjugases. This  is  important because the type of ubiquitin 
linkage determines the fate of each substrate protein and dysregulation in this system 
could be a potential factor in disease. 
4.2  Recombinant HRD1 forms polyubiquitin chains in vitro with Ube2G2 and 
Ube2J1
 In order to examine the type(s) of ubiquitin chains HRD1 forms with the ubiquitin-
conjugases it is known to interact, we used an in vitro biochemical system using purified 
proteins. This  allowed us to precisely understand the potential HRD1/ubiquitin-
conjugase functional interaction. In order to asses ubiquitin linkages made by HRD1, we 
used a recombinant HRD1 construct that contained the catalytic RING domain and the 
remainder of the cytoplasmic domain of the protein (Figure 4A; red arrow to amino acid 
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617). This recombinant HRD1 excludes the ER luminal portion and transmembrane 
domains of the ligase listed in black font in the HRD1 amino acid sequence (Figure 4B). 
The cytoplasmic amino acid residues of HRD1 are listed in red, and highlights 
individually the catalytic cysteine in the RING domain (green; Figure 4B), lysine 
residues mutated in future experiments (blue; Figure 4B), and the arginine motif of 
HRD1 that binds VCP/p97 (purple; Figure 4B).
 We first wanted to test the activity of the recombinant HRD1 in vitro so we 
examined its ability to form ubiquitin chains with four different E2 ubiquitin-conjugases: 
UbcH5C (which has been reported to function in vitro with HRD1 [118]), Ube2G2, 
Ube2J1, and Ube2W (a novel E2 ubiquitin-conjugating enzyme that enhances the 
activity of certain ubiquitin ligases, such as CHIP [195]). HRD1 made in bacteria 
generates polyubiquitin species with UbcH5C rapidly (Figure 10A). Without an E2 
ubiquitin-conjugase present in the reaction, our recombinant HRD1 protein does not 
produce any ubiquitin conjugates (Figure 10A). The arrow in the anti-ubiquitin blot for 
the reaction containing UbcH5C identifies where the unmodified version of HRD1 would 
migrate. The anti-HIS blot shows the progressive ubiquitination of HRD1 (Figure 10A). 
Examining the interaction between HRD1 and the ubiquitin-conjugase Ube2W shows 
something slightly different. Unlike with UbcH5C, HRD1 in the presence of Ube2W 
forms only mono-ubiquitin species (Figure 10B). 
 Next, we wanted to examine the activity of recombinant HRD1 with the ubiquitin-
conjugases Ube2G2 and Ube2J1 (Figure 11). Indeed, HRD1 forms polyubiquitin 
linkages in the presence of both Ube2G2 (Figure 11A) and Ube2J1 (Figure 11B). 
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FIGURE 10: HRD1 FORMS DIFFERENT UBIQUITIN CHAINS WITH 
UBCH5C AND UBE2W
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FIGURE 10: In vitro ubiquitination assays demonstrating the activity of recombinant 
HRD1 to form ubiquitin conjugates in the presence of UbcH5C (A) and Ube2W  (B). 
Reactions were set up  as described in Materials and Methods. Aliquots were taken at 
specific time points listed above and loaded onto SDS-PAGE gels for western blotting. 
Arrow in (A) identifies where the unmodified version of HRD1 would migrate. Western 
blots are representative of at least three independent experiments, with similar results.
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FIGURE 11: HRD1 FORMS POLYUBIQUITIN CHAINS WITH UBE2G2 AND UBE2J1
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FIGURE 11: In vitro ubiquitination assays demonstrating the activity of recombinant 
HRD1 to form ubiquitin conjugates in the presence of Ube2G2 (A) and Ube2J1 (B). 
Reactions were set up  as described in Materials and Methods. Aliquots were taken at 
the specific time points and loaded onto SDS-PAGE gels for western blotting. Long 
exposure for anti-His blot in (B) is to demonstrate ubiquitinated HRD1 bands. Blots 
are representative of at least three independent experiments, with similar results.
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FIGURE 12: UBE2W ENHANCES POLYUBIQUITIN CHAIN FORMATION
FIGURE 12: In vitro ubiquitination assays demonstrating the activity of recombinant 
HRD1 to form ubiquitin conjugates in the presence of Ube2G2 (A) and the equimolar 
concentration of both Ube2G2 and Ube2W  (B). Reactions were performed as 
described in Materials and Methods. Aliquots were taken at the specific time points 
and loaded onto SDS-PAGE gels for western blotting. Blots are representative of at 
least three independent experiments, with similar results.
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Based on the anti-ubiquitin and anti-HIS western blots, the chains formed by HRD1 in 
vitro in the presence of Ube2G2 are composed of unanchored chains, as  well as 
unmodified and auto-ubiquitinated Ube2G2 and HRD1 (Figure 11A; modified species 
denoted by arrows). Conversely, recombinant HRD1 in the presence of Ube2J1 forms 
predominantly unmodified and ubiquitinated Ube2J1 and little ubiquitinated HRD1 
(Figure 11B; little ubiquitin signal in upper portion of ubiquitin blot - long exposure to 
emphasize ubiquitinated HRD1). This is additional evidence that perhaps HRD1 and 
Ube2J1 require collaborations with other protein partners  to form ubiquitin conjugates, 
as compared to the readily formed ubiquitin chains by HRD1 with Ube2G2.
 Interestingly, Ube2W dramatically enhances polyubiquitin chain formation by 
HRD1 and Ube2G2 (Figure 12). Because Ube2W itself cannot directly lead to ubiquitin 
chain formation (Figure 10B) with HRD1 or with another ligase tested [195], these data 
indicate that Ube2W controls the ubiquitin chain forming activity of HRD1, and suggests 
that it might regulate HRD1 in cells.
4.3 Recombinant HRD1 forms specific ubiquitin linkages in vitro
 Knowing that HRD1 forms polyubiquitin chains  with at least Ube2G2 and Ube2J1 
in vitro (Figure 11), we wondered if HRD1 displays any type of ubiquitin linkage 
specificity (Figure 13) with these ubiquitin conjugases. To do this, we utilized 
recombinant ubiquitin mutants  that contain only a single lysine residue on ubiquitin, with 
the other six lysine residues mutated to non-ubiquitinatable arginine. In the presence of 
UbcH5C, recombinant HRD1 does not display much ubiquitin chain specificity, forming 
various types of linkages (Figure 13A). On the other hand, HRD1 and Ube2G2 form 
specifically K48-linked ubiquitin chains 
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FIGURE 13: HRD1 DISPLAYS UBIQUITIN CHAIN PREFERENCE IN VITRO
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FIGURE 13:  In vitro ubiquitination assays where recombinant UbcH5C (A), Ube2G2 
(B), and Ube2J1 (C) was combined with HRD1 in the presence of single ubiquitin 
mutants, where the ubiquitin construct contains only one ubiquitin residue, or none at 
all (KØ). Each reaction was timed for one hour and the product was loaded for 
western blotting. The Ube2J1 arrow in (C) identifies ubiquitinated Ube2J1 protein. 
Each panel is a representative western blot from at least three separate experiments, 
with similar results.
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(Figure 13B). This is important and physiologically significant because K48-linked 
chains predominantly target substrate proteins  to the proteasome for degradation [69]. 
Interestingly, HRD1 in the presence of Ube2J1 mostly forms unconventional K11-, K29-, 
and K33-linked ubiquitin species. K29-linked polyubiquitin chains have recently been 
proposed to be present within branched and/or mixed ubiquitin chains that are 
composed of other polyubiquitin linkages [208]. Additionally, these non-canonical chains 
have historically been linked to proteasome-independent substrate degradation via 
lysosomes and have diverse roles in cellular regulation [209-212]. Although the function 
of these alternative ubiquitin chains  in ERAD is  not well known, our data suggest that 
the type of polyubiquitin chain HRD1 forms in vitro depends on the ubiquitin-conjugase 
present.
 These results  regarding HRD1 displaying ubiquitin chain preference depending on 
the ubiquitin-conjugase with which it interacts are interesting because literature 
research has not shed light on HRD1 chain specificity with varying conjugases in ERAD. 
Other data in the field have demonstrated that the type of ubiquitin linkage formed by 
ubiquitin ligases in the RING family is  determined by the E2 conjugase that it interacts 
with [213, 214]. Examples of this include the ligases CHIP and BARD1-BRCA1, which 
form K48- or K63-linkages depending on the ubiquitin-conjugase the ligases interact 
with [215-217]. Together, our results (Figure 11, 13) indicate this is  the case for HRD1 
as well.
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CHAPTER 5 - HRD1 REQUIRES UBIQUITIN-CONJUGASES UBE2G2 AND UBE2J1 
IN CELLS TO FORM UBIQUITIN LINKAGES
5.1 General introduction and hypothesis
 Using in vitro protein biochemistry is an efficient way to determine the functional 
relationships between proteins. The in vitro experiments (Figures 10-13) suggest that 
the type of polyubiquitin generated by HRD1 depends on the ubiquitin-conjugase 
present in the complex. Consequently, we sought to identify how HRD1 forms specific 
ubiquitin linkages in cells, and hypothesized that HRD1 requires either Ube2G2 or 
Ube2J1 to form polyubiquitin chains on protein substrates in cells. To do this, we used 
transient transfections and co-immunoprecipitations to identify specific ubiquitin chains 
formed by HRD1. Additionally, we used ubiquitin antibodies that specifically detect K48-
linked or K63-linked polyubiquitin. We did not have access to ubiquitin antibodies 
specific to other lysine residues. The results from these experiments will help identify 
the collaborations HRD1 forms in cells, which may be useful for delineating the 
regulation of ubiquitination in ERAD.
5.2 HRD1 does not exclusively auto-ubiquitinate in cells 
 In order to identify the ubiquitin chains formed by HRD1 in cells, we examined the 
polyubiquitin species co-immunoprecipitated by HRD1. Due to its innate role as an E3 
ubiquitin ligase, HRD1 can self-ubiquitinate (e.g. Figure 11). Because we wanted to 
ensure the polyubiquitin species  co-immunoprecipitated by HRD1 are not anchored 
onto HRD1 itself, we created a lysine-deficient HRD1 construct where the lysine 
residues in the cytoplasmic portion of the protein after the transmembrane domain are 
mutated into the similar, but non-ubiquitinatable amino acid arginine (Figure 4). As 
demonstrated in Figure 14, the wild type version of HRD1 and its lysine-deficient 
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counterpart each co-immunoprecipitate similar amounts of polyubiquitin, providing 
support that the polyubiquitin species immunoprecipitated by HRD1 are not auto-
ubiquitinated HRD1 species (Figure 14). Additionally, the catalytic RING activity of 
HRD1 is essential for it to co-immunoprecipitate ubiquitin conjugates. Using a 
catalytically inactive version of HRD1 (cysteine 291 mutated to alanine [118]), the 
mutant HRD1 co-precipitates very little ubiquitin species compared to the wild type 
version (Figure 15A). The small amount of polyubiquitin species  we do see co-
precipitate with the inactive version of HRD1 is  likely due to endogenous HRD1 
because HRD1 proteins are able to interact with each other in cells (Figure 15B).
5.3 HRD1 forms K48- and K63-linked ubiquitin species in cells with the ubiquitin-
conjugases Ube2G2 and Ube2J1
 For us  to identify the importance of the ubiquitin-conjugases Ube2G2 and Ube2J1 
with HRD1 in the formation of polyubiquitin chains, we co-transfected small interfering 
RNA (siRNA) targeting the endogenous conjugases alongside wild type HRD1 (Figure 
16). In the presence of endogenous Ube2J1 (Figure 16A) and Ube2G2 (Figure 16B), 
wild type HRD1 co-precipitates  K48- and K63-linked polyubiquitin conjugates. 
Conversely, RNAi-dependent knockdown of Ube2J1 (Figure 16A) and Ube2G2 (Figure 
16B) leads to a significant decrease in the amount of co-precipitated polyubiquitin 
species by HRD1 in cells. Because the knockdown of each ubiquitin-conjugase in cells 
leads to a decrease in K48-linked and K63-linked polyubiquitin, this  indicates that HRD1 
does indeed make at least both K48 and K63 polyubiquitin chains in cultured 
mammalian cells with Ube2G2 and Ube2J1.
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FIGURE 14: CO-IMMUNOPRECIPITATED POLYUBIQUITIN SPECIES BY HRD1 ARE 
NOT AUTO-UBIQUITINATED HRD1
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FIGURE 14: HEK-293T cells were transfected with the indicated constructs and 
harvested 48 hours post-transfection. Harvested cells were lysed and incubated with 
bead-bound antibody against the V5-tag on HRD1. Immunoprecipitated protein was 
loaded onto SDS-PAGE gels for western blotting. The anti-K63- and anti-K48-linked 
ubiquitin antibodies are specific to polyubiquitin formed on lysine 63 and 48 
respectively, while the anti-ubiquitin antibody is not reported to distinguish against 
different ubiquitin linkages. K-R: lysine to arginine mutations in the cytoplasmic 
domain of HRD1 for all four lysine residues. The panel represents at least three 
separate independent experimental repeats with similar outcomes.
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FIGURE 15: THE CATALYTIC RING DOMAIN IS IMPORTANT FOR HRD1’S 
LIGASE FUNCTION
Anti-Myc (9e10) Anti-Myc (9e10)
Input
IP
(Myc-HRD1)
Anti-V5 Anti-V5
Ve
cto
r
My
c-H
RD
1
My
c-H
RD
1 C
A
Ve
cto
r
My
c-H
RD
1
My
c-H
RD
1 C
AV5-HRD1 + V5-HRD1 +
Anti-VCP
(endogenous)
Anti-VCP
(endogenous)
VCP/p97
250
150
100
75
Anti-Ubiquitin Anti-Ubiquitin
Anti-HRD1 Anti-HRD1
HR
D1
 C
A
HR
D1
 W
T
Ve
cto
r
Input
IP
(Myc-HRD1)
HR
D1
 C
A
HR
D1
 W
T
Ve
cto
r
50
HA-Ubiquitin + HA-Ubiquitin +
A B
FIGURE 15: (A, B) HEK-293T cells were transfected with the indicated constructs and 
harvested 48 hours post-transfection, lysed and incubated with bead-bound antibody 
against the Myc-tag on HRD1. Immunoprecipitated protein was loaded onto SDS-
PAGE gels for western blotting after elution through a combination of SDS and heat. 
CA: cysteine 291 to alanine mutation in the RING domain of HRD1 making it 
catalytically inactive. For each panel, western blots are representative of at least three 
separate independent trials with similar outcomes.
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FIGURE 16: KNOCKDOWN OF ENDOGENOUS UBIQUITIN-CONJUGASES IN 
CELLS IMPACTS THE ABILITY OF HRD1 TO MAKE POLYUBIQUITIN CHAINS
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FIGURE 16: (A, B) HEK-293T cells were transfected with the indicated constructs and 
harvested 48 hours post-transfection, lysed and incubated with bead-bound antibody 
against the V5-tag on HRD1 for 6 hours. Immunoprecipitated protein was loaded onto 
SDS-PAGE gels for western blotting after washing and elution through a combination 
of SDS and heat. The histograms for each western blot represent the quantification of 
the ubiquitin signal in each IP lane, normalized to the HRD1 signal in the IP lanes +/- 
standard deviations (SD), then normalized to the polyubiquitin co-immunoprecipitated 
by wild type HRD1. Error bars represent SD. P values are calculated from two-tailed 
Student T-tests. For each panel, western blots are representative of at least three 
separate independent trials with similar outcomes.
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 However exciting, these results  (Figure 16) do not coincide with the role of 
polyubiquitin chain formation by HRD1 demonstrated using in vitro biochemistry (Figure 
13) where we observe the generation of K48-linked ubiquitin chains by the partnership 
of HRD1 and Ube2G2, and the formation of non-canonical (K11-, K29-, K33-linked 
ubiquitin) chains by HRD1 with Ube2J1. In cells, HRD1 generates at least K48- and 
K63-linked polyubiquitin with either conjugase (Ube2G2 or Ube2J1) present (Figure 16). 
Together, these data indicate the need for the use of the HRD1 holo-enzyme in 
polyubiquitin chain formation made with either ubiquitin-conjugase. This is  likely the 
case especially for Ube2J1, because in vitro we do not observe K48-linked ubiquitin 
chains being formed by the HRD1/Ube2J1 partnership. Alternatively, as previously 
discussed, HRD1 and the ubiquitin-conjugases Ube2G2 and Ube2J1 may interact with 
other proteins that assist in this collaboration to make specific types of chains in 
different model systems (in vitro versus in cells). 
 Interestingly, HRD1 seemingly demonstrates the ability to form K63-linked ubiquitin 
chains in cells (Figure 16). K63-linked ubiquitin species are generally believed to 
function in non-proteasomal roles, such as  autophagy [218]. This  suggests that HRD1 
may have additional roles outside the realm of ERAD that depend on its  ability to form 
K63-linked ubiquitin chains, or perhaps some ERAD protein substrates  are degraded by 
K63-linked ubiquitin signaling.
5.4 The VCP/p97 binding domain on HRD1 is important for polyubiquitin chain 
formation
 As previously detailed, VCP/p97 is  a AAA ATPase that monitors  critical steps  in 
several protein quality control processes, including ERAD [123, 219]. The dogma 
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surrounding VCP/p97 is that it functions post-ubiquitination of protein substrates, aiding 
in their extraction into the cytosol and guiding them to the proteasome for degradation 
[130, 131]. Unlike in yeast, HRD1 directly interacts  with VCP/p97 in mammalian cells 
through an arginine rich, four amino acid long motif near its C-terminal end [110, 111]. In 
order to investigate the importance of this VCP/p97 binding domain on HRD1 in the 
generation of polyubiquitin chains, we used site-directed mutagenesis to change the 
RRRR VCP/p97 binding sequence on HRD1 into AARA, which prevents HRD1 from 
binding endogenous VCP/p97 protein (Figure 17).
 By expressing HRD1 that does  not bind VCP/p97 (referred to as HRD1-AARA) in 
mammalian cells, we found that HRD1-AARA co-immunoprecipitates less polyubiquitin 
than the wild type version of HRD1 with its VCP/p97 binding domain intact (Figure 18). 
This  suggests that while the interaction between VCP/p97 and HRD1 is  not absolutely 
necessary for the generation of polyubiquitin by HRD1, it is important for the formation 
of some species. 
 The findings from figures 14-18 lead us to surmise that the HRD1-associated 
ubiquitin species are ones formed by this E3 ligase, potentially on its substrates: the 
abundance of the ubiquitin species co-immunoprecipitated by HRD1 depends on its 
activity, is not reduced by lysine-to-arginine mutations in the cytoplasmic region of 
HRD1 thus addressing the concern that they are self-ubiquitinated HRD1 species, and 
is  not fully eliminated by preventing catalytically inactive HRD1 (HRD1-CA) from binding 
to VCP/p97. The identity of the ubiquitinated proteins remains to be determined and 
would benefit from mass-spectrometry analyses of HRD1-associated complexes from 
cells.
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 Our data hint that VCP/p97 may play multiple regulatory roles during ERAD: not only 
during substrate extraction and degradation, but possibly also during ubiquitination. 
VCP/p97 is  a critical component of cellular processes; mutations in it lead to disease 
and it is encoded by an essential gene [220, 221]. Historically, this AAA ATPase is 
thought to unwind proteins out of the ER toward proteasomal “delivery”, or to function as 
a segregase by removing from the ER proteins prone to proteolytic degradation [124, 
125, 130, 222]. The HRD1 interaction with VCP/p97 is  perhaps a regulatory feature for 
this  ligase in vivo. Figure 7 demonstrates that some of the predicted protein coding 
isoforms of the hrd1 gene in mice do not contain the VCP/p97 binding domain. It is 
possible that the expression of these particular HRD1 isoforms that do not directly 
interact with VCP/p97 controls the polyubiquitin linkages generated by the ligase and 
therefore impacts the types  of substrates targeted by ERAD for degradation. The role of 
VCP/p97 in the regulation of polyubiquitin chain formation by HRD1 could be an 
evolutionary development in vertebrates (Figure 19), and perhaps indicates an 
enhancement in the tuning of the ERAD pathway in higher organisms. Precisely how 
VCP/p97 might regulate HRD1 activity is not clear, but could involve the AAA ATPase 
functioning as a scaffold for various HRD1 partners during the ubiquitination of some 
ERAD substrates. 
 There is  another potential explanation that may account for the reduction in ubiquitin 
species co-immunoprecipitated by HRD1 that does not bind VCP/p97. VCP/p97 binds 
ubiquitin species through various interactors. Therefore, precluding HRD1 from 
interacting with VCP/p97 could lead to a reduction in ubiquitin species 
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FIGURE 17: MUTATION IN THE VCP/p97 BINDING SITE ON HRD1 PRECLUDES 
BINDING TO ENDOGENOUS VCP/p97 PROTEIN
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FIGURE 17: HEK-293T cells were transfected with the indicated constructs and 
harvested 48 hours post-transfection, lysed and incubated with bead-bound antibody 
against the Myc-tag on HRD1 for 6 hours. Immunoprecipitated protein was loaded 
onto SDS-PAGE gels for western blotting after washing and elution. Transfected 
conditions were done in duplicate for each experimental repeat and were loaded with 
equal volumes of lysate. Western blots are representative of at least three separate 
independent trials with similar outcomes.
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FIGURE 18: VCP/p97-BINDING DOMAIN OF HRD1 IS IMPORTANT TO MAKE 
POLYUBIQUITIN CHAINS IN CELLS
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FIGURE 18: HEK-293T cells were transfected with the indicated constructs. Cells 
were harvested 48 hours post-transfection, lysed and incubated with bead-bound 
antibody for 6 hours. Immunoprecipitated protein was loaded onto SDS-PAGE gels for 
western blotting. Histograms represent the quantification of K48 and K63 ubiquitin 
signal in the IP lanes, normalized to the HRD1 signal in IP +/- standard deviations 
(SD). Error bars represent SD and P values were calculated using two-tailed Student 
T-tests. Western blots are representative of at least nine separate independent trials 
with similar outcomes.
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co-immunoprecipitated by HRD1 simply as a result of removing a contribution by 
ubiquitin species bound to the AAA ATPase. This explanation, however, is not likely 
since catalytically inactive HRD1 does not co-immunoprecipitate appreciable levels of 
ubiquitin species (Figure 15A and other data not shown), even though this form of the 
ligase does bind VCP/p97 (Figure 15A). We conclude that the reduction in ubiquitin 
species as a result of the inability of HRD1 to interact with VCP/p97 is due to diminished 
polyubiquitin chain formation by the ligase when it does not bind VCP/p97.
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FIGURE 19: PREDICTED HRD1 GENES IN DIFFERENT MODEL ORGANISMS
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FIGURE 19: The predicted protein coding isoforms of HRD1 obtained by the Ensembl 
Genome Browser [205] were aligned using ClustalW2. The VCP/p97 binding motif on 
each isoform is highlighted in red font and is noticeably conserved throughout 
vertebrate species selected.
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CHAPTER 6 - THE COLLABORATION BETWEEN HRD1 AND DEUBIQUITINATING 
         ENZYMES IN ERAD
6.1 General introduction
 As has been reiterated several times, ubiquitination of misfolded, toxic, or short-
lived proteins  is central to ERAD and, more generally, to protein quality control. This 
ubiquitination is important for maintaining cellular homeostasis by helping prevent the 
accumulation of proteins in the lumen or cytoplasm that could potentially lead to severe 
human diseases including malignancy and neurodegeneration. Ubiquitination is 
reversible and deubiquitination, accomplished by proteases called deubiquitinating 
enzymes (DUBs), is critical for cell function [139, 223]. The roles of DUBs in ERAD have 
been summarized in Section 1.3; however some further detail will be supplied here 
regarding the role(s) of two different DUBs and their collaboration with HRD1: ataxin-3 
and USP25. 
 A major question in ERAD is  unresolved: How is the balance between protein 
degradation and protein rescue achieved? Functional interactions between E3 ubiquitin 
ligases (which can target proteins  for proteasomal degradation), DUBs (which can 
reverse protein ubiquitination and rescue degradation), and proteasome shuttle proteins 
(like VCP/p97) are at the crux of optimal protein quality control. Therefore, we 
hypothesized that functional interactions between HRD1 and ataxin-3 or USP25, and 
VCP/p97 and ataxin-3 or USP25 dictate the turnover of ERAD substrates.
6.2 Ataxin-3 and ERAD
 Ataxin-3 has been implicated in ERAD [146, 196], although its exact roles are 
uncertain. Two groups have reported divergent roles for ataxin-3 function in protein 
quality control. One group reported that ataxin-3 competes with ubiquitinated ERAD 
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substrates for binding to VCP/p97, essentially reducing the degradation of misfolded ER 
proteins [196]. Conversely, another report proposed that ataxin-3 deubiquitinates 
substrates bound by VCP/p97 at the proteasome, enhancing their delivery to be 
enzymatically degraded [146]. It is possible that ataxin-3 can both inhibit and facilitate 
degradation of ERAD substrates, depending on the ERAD components with which it 
interacts. VCP/p97 is not the only ERAD component with which ataxin-3 interacts; the 
other as  mentioned in detail in Chapters 3-5, is HRD1 [146], the ER-resident ubiquitin 
ligase that is upstream of VCP/p97 in ERAD [107]. To understand the role(s) ataxin-3 
plays in ERAD, and whether its functions are impacted by pathogenic expansion in its 
polyglutamine region, we conducted work in vitro and in mammalian cells.
6.2.1 Ataxin-3 interacts with HRD1 in cells 
 To begin to understand the collaboration between ataxin-3 and HRD1 in cells, co-
immunoprecipitation experiments between this DUB and E3 ubiquitin ligase were 
performed and it was determined that these two proteins do indeed interact in cells 
(Figure 20A). In contrast to wild type ataxin-3, a pathogenic version of ataxin-3 with an 
extended polyglutamine region interacts less readily with HRD1 (Figure 20A). Neither 
wild type nor pathogenic ataxin-3 have trouble co-precipitating VCP/p97 (Figure 20B). 
Additionally, HRD1 co-precipitated endogenous ataxin-3 from cells  (Figure 20C) and 
VCP/p97 can co-precipitate endogenous ataxin-3 as well (Figure 20D). Because 
ataxin-3 and HRD1 co-immunoprecipitate in transient transfections, and transfected 
HRD1 could co-precipitate endogenous ataxin-3, we wanted to use antibodies to HRD1 
and ataxin-3 to examine their endogenous co-localization using immunofluorescence 
(described in Materials and Methods). Indeed, ataxin-3 and HRD1 co-localize in
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FIGURE 20: ATAXIN-3 INTERACTS WITH HRD1 AND VCP/p97 
IN MAMMALIAN CELLS
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FIGURE 20: HEK-293 cells were transiently transfected with the indicated constructs. 
48 hours later, FLAG-ataxin-3 or Myc-ataxin-3 was immunoprecipitated using bead-
bound anti-FLAG or anti-Myc antibody. (A, B) Wild type and pathogenic ataxin-3 co-
precipitate HRD1 (A) or VCP/p97 (B). Note that less HRD1 co-precipitates with 
pathogenic ataxin-3 (red arrow). (C, D) Endogenous ataxin-3 co-precipitates with 
transiently transfected HRD1 or VCP/p97 from HEK-293 cells.
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FIGURE 21: ATAXIN-3 CO-LOCALIZES WITH THE UBIQUITIN LIGASE HRD1 
IN MAMMALIAN CELLS
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FIGURE 21: Fluorescent images of HeLa cells transfected with Myc-HRD1 and 
stained for the Myc-tag, as well as endogenous ataxin-3. Arrows and sections identify 
co-localization of HRD1 and ataxin-3.
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mammalian cells (Figure 21; arrows).
 We next investigated if ataxin-3 opposes the ubiquitin ligase activity of HRD1 in 
cells. As shown in Figure 22, HRD1 leads to lower steady state levels of a classical 
ERAD substrate, CD3δ, as also previously reported [118]. Wild type ataxin-3 opposes 
the effect of HRD1 on CD3δ protein levels in a manner that depends on its DUB 
catalytic activity. These data suggest that ataxin-3 opposes the targeting for degradation 
of ERAD substrates by HRD1. This could be through direct deubiquitination of ERAD 
substrates by ataxin-3.
6.2.2 Ataxin-3 reduces polyubiquitin chains formed by HRD1 in vitro
 We next examined if ataxin-3 modifies polyubiquitin chains formed by HRD1 in 
vitro. To investigate the functional interaction of HRD1 with ataxin-3, wild type ataxin-3 
was incubated in the same biochemical reactions  as Figures  10-13 (described in 
Materials  and Methods). In the presence of ataxin-3, the rate of formation of 
polyubiquitin chains is dramatically decreased (Figure 23), suggesting that ataxin-3 
disassembles ubiquitin chains formed by HRD1. Additionally, the effect of ataxin-3 on 
HRD1 chain formation depends on its  DUB enzymatic activity (Figure 24). Together, 
these data (Figures  20-24) help elucidate the regulatory role for ataxin-3 in HRD1 
turnover by suggesting that ataxin-3 functions with HRD1 in ERAD related duties, but 
ataxin-3 works to oppose HRD1’s innate ubiquitin ligase function by opposing HRD1-
dependent substrate turnover in cells and reducing polyubiquitin chains in vitro. 
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FIGURE 22: ATAXIN-3 OPPOSES HRD1’S EFFECT ON STEADY STATE LEVELS OF 
THE ERAD SUBSTRATE CD3δ
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FIGURE 22: HEK-293 cells were transiently transfected as indicated. Western blots of 
whole cell lysates harvested 48 hours post-transfection. HRD1 decreases steady state 
levels of CD3δ and ataxin-3 opposes this  effect in a manner that depends on its 
catalytic activity. Western blot is representative of three, independent experimental 
repeats each with similar results.
70
FIGURE 23: ATAXIN-3 OPPOSES HRD1 ACTIVITY IN VITRO
FIGURE 23: Western blot of in vitro biochemical reactions containing the specified 
components (0.3 μM E1 activating enzyme, 1 μM Ube2G2 (E2) and HRD1 (E3), 60 
μM ubiquitin, 1 μM ataxin-3, 5 mM MgCl2/ATP). Note the ability of recombinant 
ataxin-3 to reduce the levels of ubiquitinated species formed by HRD1 and Ube2G2 in 
vitro. Below is a semi-quantification of data.
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FIGURE 24: ATAXIN-3 DUB ACTIVITY IS NECESSARY TO DISASSEMBLE CHAINS 
FORMED BY THE LIGASE HRD1
FIGURE 24: Ubiquitination reactions were stopped after 90 minutes with excess 
EDTA; 1 μM ataxin-3 was added and fractions were collected as indicated. 
Catalytically active ataxin-3 rapidly cleaves ubiquitin chains after they are formed.
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6.3 Ubiquitin-specific 25 (USP25) and ERAD
 Similarly to ataxin-3, ubiquitin-specific 25 (USP25) is a catalytically active DUB in 
vitro [188, 224]. USP25 has previously been implicated in regulating the proteasomal 
turnover of muscle proteins [188]. We wondered if USP25 functions in ERAD with HRD1 
and other known components. The work presented in this  section was originally 
published in PLoS ONE [201], where I was a co-author responsible for conducting 
experiments and analyzing corresponding data.
6.3.1 USP25 interacts with ERAD proteins
 A previous study reported that the cellular distribution of USP25 (Figure 25A) 
mimics ER staining for both the wild type and muscle-specific isoforms [187]. Using 
immunofluorescence with an endogenous ER marker (KDEL; ER protein retention 
receptor 1), we found that USP25 does indeed co-localize at the ER (Figure 25B; Panel 
IC, II, III). We proceeded to use mammalian cells and co-immunoprecipitations to 
examine if USP25 physically interacts with known ERAD proteins. We found that 
transiently transfected USP25 does co-precipitate the ubiquitin ligase HRD1, as well as 
endogenous VCP/p97 (Figure 25C). The opposite experiment confirms that exogenous 
HRD1 co-precipitates USP25 and endogenous VCP/p97 protein (Figure 25D). 
Furthermore, HRD1 is able to co-precipitate endogenous USP25 in cells (Figure 25E), 
but interestingly, USP25 does not seem to physically interact with other E3 ligases 
reported to function in ERAD: UFD2/E4B (Figure 25F) and GP78/AMFR (Figure 25G). 
Together, these data imply that USP25 is able to selectively interact with at least two 
ERAD proteins.
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6.3.2 USP25 regulates the turnover of various ERAD substrates
 CD3δ is a classic ERAD substrate [101, 118, 225] and we have shown its turnover 
to be dependent on the activity of HRD1 confirming the findings of other reports  [118] 
(Figure 22). We proceeded to test if USP25 can regulate the steady state levels of 
CD3δ in the same way we demonstrated with ataxin-3 (Figure 22). Both isoforms of 
USP25 increase steady state protein levels of CD3δ and this DUB seemingly rescues 
the substrate from degradation by the proteasome because MG132 treatment 
(proteasome inhibition) abolishes the stabilization in CD3δ protein levels (Figure 26A). 
Additionally, the catalytic cysteine (C178) and N-terminal ubiquitin-associated and 
ubiquitin-interacting domains of USP25 are required to increase steady state levels of 
CD3δ because mutating the catalytic residue or deletion of either ubiquitin domain 
results in decreased CD3δ protein levels (Figure 26B, 26C). USP25 and CD3δ were 
also determined to physically interact via co-immunoprecipitation experiments  and 
CD3δ can co-precipitate endogenous HRD1 and USP25 suggesting that this  ubiquitin 
ligase and DUB may each play a role in the regulation of CD3δ (Figure 26D, 26E). 
 In addition to CD3δ, β-amyloid precursor protein (APP) is  an ERAD substrate 
regulated by the ubiquitin ligase HRD1 [226]. We wondered whether USP25’s regulatory 
role with CD3δ extends to other ERAD substrates. Indeed, exogenous USP25 leads to 
increased levels of APP protein in cells, however proteasomal inhibition by the 
pharmacological inhibitor MG132 abolishes this  steady state increase (Figure 27A). This 
suggests that USP25 is important in rescuing APP from enzymatic degradation. Via 
cycloheximide pulse-chase experiments, USP25 slows down the turnover of APP 
(Figure 27B) suggesting that USP25 over-expression increases APP half-life dependent  
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 FIGURE 25: USP25 SELECTIVELY CO-PRECIPITATES ERAD PROTEINS
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FIGURE 25: (A) Cartoon representation of known mammalian isoforms of wild type 
(WT) or muscle-specific (m) USP25. (B) HEK-293 cells were transfected with the HA-
USP25 DNA construct and 48 hours post-transfection, the cells were fixed and 
imaged as described in materials and methods. Panels IA, IB, and IC are sections (1 
μM) of a cell labeled for ER (KDEL), HA-USP25, and nucleus (DAPI). Panel IC is the 
merged image of IA and IB. Panels II and III are merged images of different cells 
under the same conditions. Scale bar represents 10 μM. (C-G) HEK-293 cells were 
transfected as indicated and immunopurified with bead-bound antibody specific to the 
protein tag of interest. Eluates were loaded onto SDS-PAGE for western blotting. 
Western blots are representative images of several, independent repeats with similar 
results.
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FIGURE 26: USP25 PREVENTS THE DEGRADATION OF CD3δ
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FIGURE 26: (A-C) HEK-293 cells were transfected as described and treated with the 
MG132 proteasome inhibitor, or cycloheximide to inhibit protein synthesis as 
indicated. Pharmacological treatments were added to cells 48 hours after initial 
transfection and cells were subsequently harvested for western blotting. WT: wild type. 
USP25(m): muscle-specific isoform. C178S: catalytic cysteine mutated to a serine 
residue [188]. ΔUIM: deletion of both UIMs. ΔUBA: deletion of the UBA. 
Quantifications represent bands from western blots and other independent 
experiments with similar results. CD3δ protein was normalized to loading control. 
Shown are means +/- standard deviations. P values were calculated from Student T-
tests. (D, E) HEK-293 cells were transfected with the indicated constructs, and 48 
hours post-transfection were immunopurified with bead-bound antibody against the 
protein tag of interest for 6 hours. Eluates were loading onto SDS-PAGE for western 
blotting.
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 on the catalytic activity of the DUB because catalytically inactive USP25 does not 
effect APP turnover (Figure 27B). 
 HEK-293 cells express endogenous APP; therefore we wanted to test USP25 
rescue without over-expressing the DUB, mimicking more physiological conditions. We 
examined steady state APP levels while knocking down USP25 via shRNA transfection 
to test whether decreased endogenous protein levels  of USP25 decreases 
endogenously expressed APP. Despite achieving only modest knockdown in cells, a 
decrease in endogenous USP25 protein reduces endogenous APP steady state levels 
(Figure 27C). Together with the knowledge that USP25 and APP co-immunoprecipitate 
in cells (Figure 27D), these results  implicate this DUB in the regulation of APP 
degradation. 
 Although the evidence presented here implicates USP25 in the regulation of ERAD 
substrate degradation, we also examined the possibility that this DUB acts on both 
ERAD and non-ERAD substrates. Using the ERAD substrate CFTRΔF508 [107] and the 
non-ERAD substrates Ub-R-GFP [197] and GFP-ODC [198], we determined that USP25 
does affect the steady state levels of CFTRΔF508, but does not impact the non- ERAD 
substrates (Figure 27E, 27F). Collectively (Figure 27), these data implicate USP25 more 
generally in the regulation of ERAD substrate turnover.
6.3.3 USP25 opposes HRD1’s ligase effect in cells 
 Because CD3δ physically interacts with both USP25 and HRD1 in cells, we 
wanted to examine the functional, combinatorial effect this DUB and ubiquitin ligase has 
on CD3δ. HRD1 decreases CD3δ steady state protein levels  in a catalytic activity-
dependent manner (Figure 28A). Similar to what we described with ataxin-3 (Figure 22),
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FIGURE 27: CERTAIN ERAD SUBSTRATES ARE DEGRADED BY USP25
FIGURE 27: (A, B) HEK-293 cells transfected with the indicated DNA constructs, and 
where noted were pharmacologically treated with MG132 or cycloheximide before 
harvesting 48 hours post-transfection. Histograms represent the quantification of 
normalized APP signal from several independent experiments. Shown are means +/- 
standard deviations and P values are calculated via Student T-tests. (C) HEK-293 
cells were transfected with shRNA constructs targeting endogenous USP25. Cells 
were harvested 48 hours after initial transfection. Semi-quantification of normalized 
APP signal are from the western blot shown, and other similar experiments. Asterisk: 
P<0.01 calculated by Student T-tests. (D) HEK-293 cells transfected with indicated 
constructs and after 48 hours, cells were lysed and immunopurified with bead-bound 
antibody to Myc-USP25. (E, F) HEK-293 cells were transfected with the indicated 
DNA constructs and lysates were loaded onto SDS-PAGE for western blotting.
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CD3δ degradation in the presence of HRD1 is rescued by exogenous USP25 (Figure 
28A), supporting a model where this DUB reverses the ubiquitin ligase function of 
HRD1. 
 To investigate the role(s) of USP25 and HRD1 on CD3δ ubiquitination, we used 
stringent immunopurification (described in Materials and Methods) to isolate CD3δ from 
HEK-293 cells. As might be expected, exogenous USP25 reduces CD3δ ubiquitination. 
Importantly, over-expression of the catalytically inactive USP25 DNA construct does  not 
noticeably change CD3δ protein levels, or its ubiquitination and degradation rates 
(Figure 28B, 28C) suggesting that this DUB may rescue CD3δ from enzymatic 
degradation by the proteasome via deubiquitination.
6.3.4 USP25 decreases HRD1- or VCP/p97-associated ubiquitin species
 Due to HRD1’s innate role as an E3 ubiquitin ligase, its  main responsibility is the 
ubiquitination of endogenous proteins in order for proteasomal degradation to occur. In 
order to examine if USP25 affects the ubiquitination status of proteins associated with 
ERAD components, we immunopurified endogenous proteins associated with HRD1 
from cells either over-expressing USP25 or not. 
 In Figure 29A, USP25 reduces the levels  of ubiquitinated species that co-
immunoprecipitate with HRD1 in a manner dependent on its  catalytic activity, and its 
ubiquitin-binding and ubiquitin-interacting motifs. Interestingly, deletion of the ubiquitin-
interacting or ubiquitin-binding regions on USP25 does not abolish its interaction with 
HRD1 (Figure 29B), together (Figure 29A, 29B) suggesting that USP25 opposes HRD1 
ligase function in cells by cleaving ubiquitin chains.
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FIGURE 28: USP25 OPPOSES HRD1’S UBIQUITIN LIGASE ACTIVITY ON 
CD3δ IN MAMMALIAN CELLS
FIGURE 28: (A) HEK-293 cells were transfected with the indicated DNA constructs, 
harvested 48 hours after the initial transfection and whole cell lysates were loaded 
onto SDS-PAGE for western blotting. WT: wild type. CA: catalytically  inactive. 
Histograms represent quantifications from this and other similar experiments. Shown 
are means +/- standard deviations where CD3δ is normalized to loading control. P 
values are calculated from Student T-tests. (B, C) HEK-293 cells were transfected with 
the indicated DNA and treated with the proteasome inhibitor MG132 for 6 hours, 48 
hours after transfection. HA-tagged CD3δ was immunopurified under stringent 
conditions (Materials and Methods). Histograms show semi-quantification of ubiquitin 
smears labeled in brackets from here and other independent results. Means +/- 
standard deviation are shown and P values calculated via Student T-tests.
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FIGURE 29: USP25 DEUBIQUITINATES ENDOGENOUS PROTEINS IN ERAD
FIGURE 29: (A-C) HEK-293 cells were transfected with the DNA constructs as 
indicated and after 48 hours, cells were harvested, lysed and immunopurified with 
bead-bound antibody specific to the V5 tag (A, B) on HRD1-associated proteins or the 
GFP tag (C) on VCP/p97-associated proteins. Histograms are semi-quantifications of 
this and other similar experiments showing means +/- standard deviations. P values 
for panels (A) and (C) are the result of Student T-tests.
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 Lastly, we tested whether USP25 affects the ubiquitination status of ubiquitin 
species associated with the proteasomal shuttle protein VCP/p97 (Figure 29C). USP25 
reduces the levels of ubiquitin species of proteins associated VCP/p97; however, the 
reduction is not as dramatic as we see with HRD1-associated proteins. Altogether, 
these data implicate USP25 in ERAD substrate turnover.
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CODA
 Protein quality control comprises a set of basic cellular pathways that are 
indispensable for all cells, tissues and organs and regulate the turnover of most cellular 
proteins. The importance of protein quality control mechanisms is underscored by 
cancers, neurological diseases and metabolic syndromes caused by or linked to 
aberrations in one of more of its components. A principal pathway in protein quality 
control is  ER-Associated Degradation (ERAD), which regulates the turnover of proteins 
synthesized in the ER by recognizing misfolded, anomalous proteins and ubiquitinating 
them for the purposes of proteasomal degradation.  
 New evidence has documented the involvement of several ERAD components in 
malignancies. In my own research, I found that HRD1, an E3 ubiquitin ligase that 
functions in ERAD, is expressed differentially by various cancer cell lines in combination 
with varying types of E2 ubiquitin-conjugases, suggesting that different ubiquitin chains 
are formed in ERAD under varying conditions. HRD1 and its collaborating ubiquitin-
conjugases are also differentially expressed in various mouse organs. Additionally, the 
expression of HRD1 and of the E2 ubiquitin-conjugases with which it functions  is 
dynamically regulated in response to stress in cell culture. Collectively, these findings 
led us to wonder whether HRD1 makes different types of ubiquitin-ubiquitin linkages 
with different E2 ubiquitin-conjugases.
" Through in vitro reconstituted systems, I determined that HRD1 and the ubiquitin-
conjugase Ube2G2 construct only K48-linked polyubiquitin. This type of chain is usually 
coupled to protein degradation by the proteasome. However, HRD1 in the presence of 
another conjugase, Ube2J1, forms unconventional (K11-, K29-, and K33-linked 
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polyubiquitin) chains. The roles of these chains in proteolytic or non-proteolytic 
processes are unclear. These results suggested that ERAD substrates are processed 
differently under specific conditions. The formation of these polyubiquitin chains was 
markedly  enhanced by a third conjugase, Ube2W, indicating that the activity and 
function of HRD1 can be directly upregulated by the conjugase with which it interacts; 
this might hold particularly during ER stress, as gene transcription of Ube2W is 
markedly increased during physiological and pharmacological stressors tied to ERAD.
" The interaction of HRD1 with the proteasomal shuttle protein VCP/p97 may 
provide an additional layer of HRD1 control by determining some types of ubiquitin 
linkages generated by the ligase, even though this direct interaction between E3 
ubiquitin ligase and VCP/p97 is not strictly required for polyubiquitin chain formation. 
The role of VCP/p97 in this system is potentially  complex: the data presented suggest 
that VCP/p97 plays a variety of regulatory roles in ERAD. Generally thought to function 
during substrate extraction from the ER and during its degradation, it is possible that 
VCP/p97 may have roles during active ubiquitination as well. 
 The idea that HRD1 forms K48-linked ubiquitin chains in cells  is  not particularly far-
fetched. Since ERAD-related ubiquitin ligases tag misfolded, toxic, or short-lived 
proteins with ubiquitin, most substrates of ligases are thought to be degraded by the 
26S proteasome and K48 ubiquitin linkages have long been associated with enzymatic 
degradation by the proteasome. However, our findings that HRD1 can make K63-linked 
ubiquitin conjugates in mammalian cells  implies that perhaps HRD1 has functions 
outside of ERAD, or even that K63-linkages may play a role in substrate degradation in 
some way, which to the best of our knowledge has not been reported in peer-reviewed 
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journals. My studies implicate the use of specific types of ubiquitin chains under diverse 
conditions in ERAD and in different tissues. Importantly, the type of ubiquitination 
occurring on HRD1 substrates is dictated not by this protein, but by its binding partners. 
This is a novel finding that will alter the way in which we think about degradative 
processes. 
 Based on the data presented here, HRD1 seems to work in concert with at least 
two DUBs during ERAD, ataxin-3 and USP25: HRD1 ubiquitinates ERAD substrates 
targeting them for degradation by the proteasome, while ataxin-3 or USP25 
deubiquitinate them rescuing the protein from degradation. Together, this work 
delineates some of the molecular mechanisms of ERAD from the perspective of ligases, 
ubiquitin-conjugases and DUBs, providing clues into the regulation of HRD1 activity in 
cells. 
 Understanding how proteins are targeted for degradation allows us to intervene 
therapeutically in cancers and other proliferative diseases at the earliest possible step 
and with the highest degree of specificity. Collectively, these data explain molecular 
mechanisms of degradation and these data will likely  aid in the identification of new 
targets for therapeutic intervention in the future.
87
FUTURE DIRECTIONS
 Collectively, this work provides new insights  into the functional interaction between 
ubiquitin-conjugases (Ube2J1, Ube2G2), a ligase (HRD1) and DUBs (ataxin-3, USP25) 
in ERAD. Unless the ERAD process is  monitored at various regulatory steps and 
through checkpoints, the interaction between its components could prove energetically 
wasteful and ultimately destructive. There could be instances when HRD1 function 
predominates (ERAD is pushed forward) and others when ataxin-3 or USP25 for 
example takes over (ERAD is  held back). How this interaction is regulated in cells must 
be further investigated. 
 Regulation of ERAD at the level of substrate ubiquitination or deubiquitination 
could occur by controlling the recruitment of DUBs to HRD1 (through direct or indirect 
interactions) or through the regulation of HRD1’s activity (e.g. by Ube2W or VCP/p97). 
One could investigate this  interaction examining HRD1-associated complexes under 
normal conditions, or at various  points  during ERAD. Using both normal and disease 
cell lines, together with cycloheximide-based transcriptional holds and releases, one 
could isolate HRD1 complexes at various stages of protein synthesis and degradation 
related to ERAD and assay them qualitatively and quantitatively through mass 
spectrometry-based approaches.
 Besides sorting out the ERAD pathway in cells  to understand the collaboration 
between proteins, aberrant ERAD, as stated earlier, is  implicated in a number of human 
diseases. Ubiquitin-dependent pathways are intrinsically central to the etiology of many 
diseases due to malfunctions in them generally causing an accumulation of toxic 
protein, essentially abolishing cellular homeostasis. In cells, it would be of interest to 
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determine what other proteins accumulate at the ER during different disease conditions. 
By isolating the ER after proteasomal inhibition in cells  or by isolating ER in different 
tissues from mice, mass spectrometry could also be able to identify protein complexes 
that function during stress and disease, compared to normal conditions. 
 Work in vivo using rodent or other model organisms would be an essential 
component to understanding how mutations in pathways such as ERAD contribute to 
the formation of cancers or neurodegenerative disease. For a quick read-out of the 
proteins important in this system, using Drosophila melanogaster that are expressing 
toxic proteins in the fly eyes, RNAi-dependent knockout of HRD1, VCP/p97, and other 
ERAD components such as DUBs through morphology, electrophysiology and western 
blotting would allow us to investigate degenerative and protective phenotypes in this 
model. This would allow us to better understand how the collaboration of these proteins 
in vivo contribute to disease, or even protect against it. Phenotypic differences in fly 
eyes will provide important molecular clues into the biology of ERAD components in 
vivo.
 It would also be of interest to further understand the type(s) of polyubiquitin chains 
formed by HRD1 or other ubiquitin ligases. Our work shows that HRD1 is  able to 
generate at least K48- and K63-linked conjugates. There are of course other lysine 
residues on ubiquitin that can form chains, each with potentially distinct molecular roles 
in ERAD and other basic cell processes. It is possible that polyubiquitin chains not 
investigated here contribute to disease pathogenesis or maybe even protection. A better 
understanding of the roles of ubiquitin linkages in specific diseases and the proteins  that 
form these linkages may allow us to better understand how to attack human pathologies 
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with small molecules and may greatly accelerate our understanding of diseases  caused 
by aberrant mechanisms of protein quality control in humans.
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 Protein Quality Control (PQC) comprises cellular pathways that regulate the 
turnover of short-lived, misfolded proteins. A main component of PQC is  Endoplasmic 
Reticulum (ER)-Associated Degradation (ERAD), which controls the degradation of 
proteins synthesized in the ER. Aberrations in ERAD have been linked to malignancies 
such as sarcomas, breast, and pancreatic carcinomas, as well as neurodegenerative 
disease. The machinery in this system is complex and while significant progress  has 
been made to understand ERAD, it is  not clear how the different components come 
together, or how they are regulated. HRD1 is a resident ubiquitin ligase that has been 
proposed as a metastasis suppressor. My goal is to understand how HRD1 is regulated 
during normal states and in disease, particularly because my own work suggests 
complex mechanisms that regulate this protein and, more generally, ERAD.
" We found that HRD1, an E3 ubiquitin ligase that functions in ERAD, along with 
other PQC components are differentially  expressed in various cancer cell lines and in 
different mouse tissues, suggesting that specific types of ubiquitin chains are formed in 
ERAD under varying conditions. These findings led us to wonder whether HRD1 makes 
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different types of ubiquitin-ubiquitin linkages with different E2 ubiquitin-conjugases. 
Through in vitro reconstituted systems, we found that HRD1 and the ubiquitin-conjugase 
Ube2G2 make only  K48-linked polyubiquitin. This type of chain is classically tied to 
protein degradation by the proteasome. However HRD1, in the presence of another 
conjugase Ube2J1, forms unconventional K11-, K29-, and K33-linked polyubiquitin 
chains. These in vitro findings suggested that ERAD substrates are processed 
differently under specific conditions. In cells, HRD1 makes at least K48- and K63-linked 
polyubiquitin chains  with Ube2G2 and Ube2J1, and the direct interaction of HRD1 with 
VCP/p97, while not required for polyubiquitin chain formation by this  E3 ligase, may 
determine some types of ubiquitin chains formed by HRD1 with either E2 conjugase. 
Our findings suggest that HRD1 has specific partners in different tissues with potentially 
different ERAD outcomes. My work has broad implications in pathophysiology; it may 
emphasize specific sites of therapeutic intervention, and will provide significant clues 
into the functional balance of protein quality control in normal and disease states.
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